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ABSTRACT 
 
Sara R. Selitsky: Small RNA transcriptomic analysis during chronic viral hepatitis and cancer 
(Under the direction of Praveen Sethupathy and Stanley M. Lemon) 
 
 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are unrelated non-cytopathic viruses 
that infect the liver1. Hundreds of millions of people worldwide are chronic carriers of HBV or 
HCV, and together these viral infections are responsible for ~80% of hepatocellular carcinoma 
(HCC). Numerous reports suggest that certain microRNAs (miRNAs, small non-coding RNAs 
that regulate gene expression post-transcriptionally2) are important in the pathogenesis of viral 
hepatitis, although very few studies have assessed them comprehensively. Furthermore, no 
study of viral hepatitis or HCC has analyzed other classes of small RNAs, such as tRNA-derived 
RNAs (tDRs). tDRs have recently been suggested to play a role in human health, although they 
have never been previously assessed in primary human tissue. 
 Our goal was to characterize thoroughly the small RNA transcriptome in chronic viral 
hepatitis and HCC. We used high-throughput sequencing to conduct an unbiased profiling of 
small (14-40 nts) RNAs in liver from Japanese subjects with advanced hepatitis B or C and 
paired HCC. We also analyzed gene expression data (microarray) and determined that 
pathways controlling cholesterol homeostasis were among the most significantly altered in 
chronic viral hepatitis and especially in HCC. An integrative analysis of miRNA and gene 
expression data predicted several candidate master miRNA regulators of each disease state, 
including miR-21 and miR-27. We validated in cell culture the roles of miR-21 and miR-27 as 
regulators of cholesterol synthesis, suggesting that these two miRNAs may be responsible in 
part for cholesterol imbalance in chronic viral hepatitis and HCC.  
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We next sought to assess tDRs in chronic viral hepatitis and liver cancer. From the small 
RNA-seq, we observed that tDRs were abundant and significantly increased in chronic viral 
hepatitis. Remarkably, tDR abundance exceeded that of miRNAs in most infected non-
cancerous tissue. In cancer tissue, the total abundance of tDRs was reduced and the relative 
abundance of individual tDRs was altered. Despite the potential relevance of tDRs to human 
health and disease, there is no standardized nomenclature, and no method has yet been 
developed to quantify tDRs from small RNA-seq datasets. To ameliorate these limitations, I 
developed a publically available method called tDRmapper. 
  
	   v 
 
ACKNOWLEDGEMENTS 
 
My project would not have been possible without the guidance, hard work, and insight of 
others. I would like to think the lab members of both the Sethupathy and Lemon labs. I am 
especially grateful to my mentors Praveen Sethupathy and Stan Lemon. I would also like to 
thank Jeanette Baran-Gale, for her role as my computational mentor. I would like to thank 
Daisuke Yamane, Takahiro Masaki, Bailey Peck, Lisa Kurtz, and Emily Fannin for their help with 
experiments. Lastly, I would like to thank our collaborators Masao Honda, Tetsuro Shimakami, 
and Robert Lanford, for their resources, which made the research possible. 
  
	   vi 
	  
TABLE OF CONTENTS 
LIST OF TABLES ......................................................................................................................... ix 
 
LIST OF FIGURES ....................................................................................................................... x 
 
LIST OF ABBREVIATIONS ......................................................................................................... xii 
 
CHAPTER 1 .................................................................................................................................. 1 
 
Introduction ............................................................................................................................... 1 
 
1.1 Hepatitis B and C viruses ................................................................................................ 1 
 
1.2 Non-coding RNAs ............................................................................................................ 2 
 
1.1a miRNAs ......................................................................................................................... 2 
 
1.1b tRNA-derived RNAs ...................................................................................................... 3 
 
1.3 Assessment of non-coding RNAs in chronic viral hepatitis  
and cancer ................................................................................................................................ 4 
 
CHAPTER 2 .................................................................................................................................. 7 
 
2.1 Overview ............................................................................................................................. 7 
 
2.2 Introduction ......................................................................................................................... 8 
 
2.3 Results ................................................................................................................................ 9 
 
2.3a Pathways mediating cholesterol homeostasis are  
prominently altered in chronic viral hepatitis and liver cancer ............................................... 9 
 
2.3b Small RNA transcriptome analysis identifies novel  
differentially expressed microRNAs in chronic viral hepatitis  
and liver cancer ................................................................................................................... 11 
 
2.3c Several microRNAs are identified as candidate master  
regulators of pathways mediating cholesterol homeostasis  
in chronic viral hepatitis and liver cancer ............................................................................ 13 
	   vii 
 
2.3d miR-27 suppresses cholesterol synthesis via regulation  
of the rate-limiting enzyme, HMG-CoA-Reductase ............................................................. 15 
 
2.3e Model of miRNA-mediated regulation of cholesterol  
metabolism in chronic viral hepatitis and associated HCC ................................................. 16 
 
2.4 Discussion ........................................................................................................................ 17 
 
2.5 Materials and methods ..................................................................................................... 19 
 
CHAPTER 3 ................................................................................................................................ 34 
 
3.1 Overview ........................................................................................................................... 34 
 
3.2 Introduction ....................................................................................................................... 34 
 
3.3 Results .............................................................................................................................. 36 
 
3.3a tRNA-half abundance is significantly increased in  
chronic viral hepatitis .......................................................................................................... 36 
 
3.3b tRNA-half abundance is altered in viral hepatitis  
associated cancer ............................................................................................................... 38 
 
3.3c tRNA-half abundance correlates with angiogenin  
levels in HBV-associated cancer ........................................................................................ 38 
 
3.4 Discussion ........................................................................................................................ 39 
 
3.5 Materials and Methods ..................................................................................................... 42 
Chapter 4 .................................................................................................................................... 56 
 
4.1 Overview ........................................................................................................................... 56 
 
4.2 Introduction ....................................................................................................................... 56 
 
4.3 Results and Discussion .................................................................................................... 59 
 
4.3a Small RNA-seq datasets from four categories of  
human cell types / tissues ................................................................................................... 59 
 
4.3b Details of tDRmapper .................................................................................................. 61 
 
4.3c Analysis of different categories of cell types/tissues  
shows that tDR profiles are specific to tissue, disease and  
stage of differentiation ......................................................................................................... 71 
 
4.4 Conclusions ...................................................................................................................... 72 
	   viii 
 
4.5 Materials and Methods ..................................................................................................... 73 
CONCLUSION ............................................................................................................................ 74 
REFERENCES ........................................................................................................................... 84 
	   ix 
LIST OF TABLES 
 
Table 2.1. Results of pathway enrichment analysis of  
chronic viral hepatitis and cancer ............................................................................................... 22 
 
Table S2.1 Clinical information of subjects assessed ................................................................. 24 
 
  
	   x 
LIST OF FIGURES 
 
Figure 1.1 tRNA-derived RNA biogenesis schematic. .................................................................. 6 
 
Figure 2.1 Global gene expression in chronic viral hepatitis 
 and cancer .......................................................................................................................... 25 
 
Figure 2.2 Expression of genes in the cholesterol synthesis  
 pathway in chronic viral hepatitis and cancer ..................................................................... 26 
 
Figure 2.3 Global miRNA expression in chronic viral hepatitis  
 and cancer .......................................................................................................................... 27 
 
Figure 2.4 Published literature on miRNAs that are differentially  
 expressed in chronic viral hepatitis and liver cancer ........................................................... 28 
 
Figure 2.5 Candidate miRNA master regulators of gene expression  
 profiles in chronic viral hepatitis and associated liver cancer ............................................. 29 
 
Figure 2.6 Candidate miRNA master regulators miR-27  
 and miR-21 control cholesterol synthesis in vitro ................................................................ 30 
 
Figure 2.7 Model of miRNA regulation of cholesterol synthesis 
  in chronic viral hepatitis and associated liver cancer ......................................................... 31 
 
Figure 2.8 Model of miRNA regulation of cholesterol transport 
  nd efflux in chronic viral hepatitis and associated cancer ................................................... 32 
 
Supplemental Figure 2.1 miR-122-3p and miR-122-5p  
 comparison. ........................................................................................................................ 33 
 
Figure 3.1 tRH abundance in HBV- and HCV-infected liver ....................................................... 45 
 
Figure 3.2 5’ tRH abundance in HBV- and HCV-associated  
 hepatocellular carcinoma .................................................................................................... 46 
 
Figure 3.3 Angiogenin expression in viral hepatitis and  
 hepatocellular carcinoma .................................................................................................... 47 
 
Supplemental Figure 3.1 ............................................................................................................. 48 
 
Supplemental Figure 3.2 ............................................................................................................. 49 
 
Supplemental Figure 3.3 ............................................................................................................. 50 
 
Supplemental Figure 3.4 ............................................................................................................. 51 
 
Supplemental Figure 3.5 ............................................................................................................. 52 
 
Supplemental Figure 3.6 ............................................................................................................. 53 
 
	   xi 
Supplemental Figure 3.7 ............................................................................................................. 54 
 
Supplemental Figure 3.8 ............................................................................................................. 55 
 
Figure 4.1 Relative abundance of all tRNA-derived RNAs  
 across four categories of human cell types/tissues ............................................................ 74 
 
Figure 4.2 Schematic of tDRmapper .......................................................................................... 75 
 
Figure 4.3 Proportion of “error types” for specific tRNA-derived 
 RNAs across different tissues and diseases ....................................................................... 76 
 
Figure 4.4 Diagrammatic representation of the naming  
 scheme for tRNA-derived RNAs ......................................................................................... 77 
 
Figure 4.5 Examples of mature tRNA coverage maps from  
 each category of human cell types/tissues ......................................................................... 79 
 
Figure 4.6 Example of pre-tRNA coverage maps ....................................................................... 80 
 
Figure 4.7 Comparison of tDR profiles across four categories 
 of human cell types/tissues ................................................................................................. 81 
 
  
	   xii 
LIST OF ABBREVIATIONS 
 
c-CHB            Chronic hepatitis B associated cancer 
c-CHC            Chronic hepatitis C associated cancer 
CHB               Chronic hepatitis B 
CHC               Chronic hepatitis C 
DE                  Differentially expressed 
HBV                Hepatitis B virus 
HCC               Hepatocellular carcinoma 
HCV               Hepatitis C virus 
IPA                 Ingenuity Pathway Analysis 
miRNA           microRNA 
mRNA            Messenger RNA 
nt                    nucleotide 
RL                  Renilla luciferase 
TCGA             The Cancer Genome Atlas 
tDR                 Transfer RNA-derived RNA 
tRF                 Transfer RNA-fragment 
tRH                 Transfer RNA-half 
tRNA              Transfer RNA 
	  	   1 
 
CHAPTER 1 
 
Introduction 
 
1.1 Hepatitis B and C viruses 
 
HBV and HCV are phylogenetically unrelated non-cytopathic viruses that infect the liver1. 
HBV is in the family Hepadnaviridae3. HBV’s genome is approximately 3,200 nts long and is a 
partially double-stranded circular DNA genome. HCV is in the family Flaviviridae3. HCV’s 
genome is approximately 9,600 nts long and is a positive-strand RNA genome. While HBV is a 
DNA virus, and HCV is an RNA virus, upon infection both can either be cleared within a few 
months4 or become chronic. Hundreds of millions of people worldwide are persistent carriers of 
HBV or HCV, 30-50% of whom develop chronic liver disease5. Together, these viral infections 
are responsible for ~60% of liver cirrhosis and ~80% of hepatocellular carcinoma (HCC), a 
leading cause of cancer-related deaths worldwide.  
HBV and HCV related HCC arises from the liver disease associated with these chronic 
infections as well as viral specific factors1. Small RNAs have also been shown to play a role in 
HCC development. For example, carcinogenesis in HCC is promoted by miR-21 targeting 
PTEN6, a tumor suppressor, and miR-224 acting as an oncogene, by activating AKT signaling7. 
The mechanisms by which HBV and HCV cause cancer is an active area of research and our 
analysis of small RNAs in these disease states contributes to the overall understanding of 
disease pathogenesis. Although there is a vaccine for HBV, there is currently no cure; 
contrastingly, there is no vaccine for HCV, but direct acting antivirals have been developed that 
are able to eliminate HCV in most patients. Discovery of novel molecular markers and drivers of 
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disease pathogenesis will lead to the development of more effective diagnostic and therapeutic 
strategies. 
 
1.2 Non-coding RNAs 
 
Non-coding RNAs are defined as RNAs that are not translated into proteins. This is a broad 
category of RNAs that includes transfer RNAs (tRNAs), ribosomal RNAs, long non-coding 
RNAs, small nucleolar RNAs, circular RNAs, piwi-interacting RNAs, microRNAs (miRNAs), and 
tRNA-derived RNAs (tDRs). Some of these non-coding RNAs have been described and studied 
for decades while others have recently been discovered through new advances in sequencing 
technology8. In this study, we focused on two classes of small non-coding RNAs, miRNAs and 
tDRs. 
Numerous studies suggest that miRNAs may be important in the pathogenesis of 
chronic viral hepatitis. However, to the best of our knowledge, only one study has attempted to 
profile small RNAs using the state-of-the-art technology, small RNA sequencing, in chronic viral 
hepatitis and cancer9. Also, no study of viral hepatitis or HCC has included an analysis of tDRs.  
1.1a miRNAs 
 
miRNAs are small (~22 nt) non-coding RNAs that regulate gene expression post-
transcriptionally2. miRNAs are loaded onto an Argonaute protein in the RNA-induced silencing 
complex, which then targets an mRNA through complementary binding of the seed region 
(generally nts 2-7) of the miRNA, leading to either inhibition of translation or increased rate of 
messenger RNA (mRNA) degradation2. In miRBase10, there are currently 2,588 mature known 
miRNAs in the human genome, and a single miRNA may be capable of targeting hundreds of 
mRNAs11.  
The importance of miRNAs in human health is a topic of extensive study. miRNAs are 
often associated with disease. Notably, miRNAs have been implicated in various cancers, 
metabolic diseases, immune disorders, and viral infections11. Due to the sequence-based 
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function of miRNAs, computational predictions of the altered regulatory interactions between 
miRNAs and mRNAs are possible by assessing mRNA and miRNA expression profiles in 
different disease states2. In Chapter 2, we described an integrative analysis of mRNA and 
miRNA profiles of subjects with chronic viral hepatitis and cancer. We determined the candidate 
miRNA master regulators of these disease states and experimentally validated the predicted 
functions of two of these miRNAs. 
1.1b tRNA-derived RNAs 
 
Transfer RNAs, or tRNAs, are non-coding RNAs that deliver amino acids to ribosomes 
during translation. tDRs are small RNAs that are enzymatically processed from either nascent 
pre-tRNA transcripts or mature tRNAs12. Multiple “types” of tDRs have been described, such as 
tRNA-halves (30-35 nts) and tRNA-fragments (<28 nts). tDR biogenesis differs depending on 
the tDR size and location of origin (Figure 1.1). tRNA-halves are created by cleavage in the 
anticodon loop by the ribonuclease Angiogenin13, which is a process induced by stress13,14. The 
relationship between tRNA-halves and Angiogenin is further explored in Chapter 3. tRNA-
fragments are processed by a variety of different enzymes, depending on their location of origin. 
tDRs derived from the 3’ trailer of the pre-tRNA are produced during tRNA maturation, by 
tRNAse Z15. Some of the tDRs that are derived from the 5’ end of mature tRNAs are Dicer 
dependent, while others are Dicer independent. tDR biogenesis is still incompletely known. 
tDR’s regulated biogenesis and well-defined 5’ and 3’ ends indicate that they are not 
stochastic products of tRNA degradation16. tDRs are generated in organisms from all domains 
of life15. They are derived from most tRNA genes, produced in varying abundance, in many 
different sizes, and from different regions of the tRNA. Several functions have been attributed to 
tDRs such as post-transcriptional gene regulation17, translational repression18, stress granule 
formation19, and protection from apoptosis20; however, all of these have been in the context of 
cell culture. 
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 The relevance of tDRs in human health is starting to emerge. For example, tDRs may be 
important immune regulators. Trypanosoma cruzi, the parasite responsible for Chagas disease, 
releases extracellular vesicles that contain a high abundance of tDRs, which promote infection 
susceptibility of mammalian cells21 by modulating the host’s immune related genes22. Another 
possible example of tDRs having an immune modulatory effect is that they are found in high 
abundance in mature mouse sperm23 and in human seminal exosomes24 (semen is a known 
immune modulator). tDRs may also be associated with neurodegeneration25. Mutations in 
angiogenin, the enzyme that cleaves a tRNA to form two tRNA-halves14, are associated with 
both amyotrophic lateral sclerosis and Parkinson disease26. Finally, tDR expression may 
increase with specific viruses; respiratory syncytial virus in A549 cells induces tDR formation, 
but not human metapneumovirus27. We hypothesized that tDRs also play a role in viral hepatitis 
pathogenesis and carcinogenesis. However, they have not been studied previously in the 
context of viral hepatitis and liver cancer, and, to the best of our knowledge, no studies have 
even assessed tDR abundance in primary human tissue. In Chapter 3, we report on the 
characterization of the tDR profile in viral hepatitis and cancer. 
Despite the potential biomedical significance of tDRs, the field is lagging behind other 
small RNA fields in terms of genomic annotation and strategies for quantification from small 
RNA-sequencing data. This is due in large part to the unique computational challenges of 
mapping tDRs from small RNA-seq data and the lack of a standardized nomenclature for tDRs. 
We developed a novel method that quantifies and annotates tDRs, tDRmapper, which is 
discussed in Chapter 4. 
1.3 Assessment of non-coding RNAs in chronic viral hepatitis and cancer 
 
This study provides a deeper understanding of how small RNAs contribute to viral 
hepatitis pathogenesis and carcinogenesis by use of microarray and small RNA-sequencing of 
chronic hepatitis B, chronic hepatitis C, and associated HCC. We defined the small RNA profiles 
of each of these disease states, determined which pathways are most significantly altered 
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compared to uninfected controls, and which determined which miRNAs are likely regulating 
these pathways (Chapter 2). We performed an in-depth analysis of tDRs and determined which 
tDR species are present and how their abundance changes during infection and in cancer 
(Chapter 3). Lastly, we developed a publically available bioinformatics tool, tDRmapper, which 
classifies and quantifies tDRs, and produces an automatic visualization of the tDR profile 
(Chapter 4). 
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Figure 1.1 tRNA-derived RNA biogenesis schematic. Schematic depicting tRNA-
derived RNA biogenesis. Adapted from Gebetsberger, J. & Polacek, N. Slicing tRNAs to 
boost functional ncRNA diversity. RNA Biol 10, 1798-1806, (2013). 
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CHAPTER 2 
 
Transcriptomic analysis of chronic hepatitis B and C and liver cancer reveals 
microRNA-mediated control of cholesterol synthesis programs 
 
2.1 Overview 
 
HBV and HCV are phylogenetically unrelated hepatotropic viruses that persistently infect 
hundreds of millions of people world-wide, often leading to chronic liver disease and HCC. 
Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated HCC are characterized by 
cholesterol imbalance and dyslipidemia; however, the key regulatory drivers of these 
phenotypes are poorly understood. Using gene expression microarrays as well as high-
throughout sequencing of small RNAs, we performed integrative analysis of miRNA and gene 
expression in non-malignant and matched cancer tissue from human subjects with CHB or CHC 
and HCC. We also carried out follow-up functional studies of specific miRNAs in a cell-based 
system. These studies led to four major findings. Firstly, pathways affecting cholesterol 
homeostasis were among the most significantly over-represented among genes dysregulated in 
chronic viral hepatitis and especially in tumor tissue. Secondly, for each disease state, specific 
miRNA signatures were identified that included miRNAs not previously associated with chronic 
viral hepatitis, such as miR-1307 in CHC. Notably, a few miRNAs, including miR-27 and miR-
224, were components of the miRNA signatures of all four disease states: CHB, CHC, CHB-
associated HCC and CHC-associated HCC. Thirdly, using a statistical simulation method 
(miRHub) applied to the gene expression data, we identified candidate master miRNA 
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regulators of pathways controlling cholesterol homeostasis in chronic viral hepatitis and HCC, 
including miR-21, miR-27, and miR-33. Lastly, we validated in human hepatoma cells that both 
miR-21 and miR-27 significantly repress cholesterol synthesis, and that miR-27 does so in part 
through regulation of the gene that codes for the rate-limiting enzyme HMG-CoA-Reductase 
(HMGCR). 
 
2.2 Introduction 
 
HBV and HCV are non-cytopathic viruses that both exhibit marked tropism for liver 
parenchymal cells and persistently infect hundreds of millions of people world-wide, often 
leading to chronic liver disease and cancer1.  Together, these viral infections are responsible for 
~80% of HCC, which is the third leading cause of cancer-related deaths.  Though HBV and 
HCV are phylogenetically unrelated viruses, chronic infections with either can lead to 
dyslipidemia and cholesterol imbalance28-31.  Liver cancer is also associated with aberrant lipid 
and lipoprotein metabolism32,33.  However, the pathogenic mechanisms underlying the 
dysregulation of lipid pathways in CHB, CHC, and HCC are poorly understood. 
miRNAs which are small RNAs that post-transcriptionally regulate gene expression, 
have emerged as critical modulators of lipid homeostasis34-36.  The first miRNA that was 
reported to control lipid pathways in the liver was miR-12237, which was also subsequently 
shown to promote HCV replication38.  Since the discovery of miR-122, several other miRNAs 
have been implicated in the control of lipid homeostasis.  For example, miR-34a contributes to 
hepatic steatosis via regulation of sirtuins39, miR-33 controls cholesterol flux through regulation 
of ATP-binding cassette transporters40-42, miR-30 regulates lipoprotein secretion by repressing 
microsomal triglyceride transfer protein43, and miR-29 fine-tunes the FOXA2-controlled gene 
network governing lipid homeostasis44.  We hypothesize that miRNAs play a key role in the lipid 
imbalance that has been observed in chronic viral hepatitis and associated HCC. 
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In this study, we performed an integrative analysis of miRNA and gene expression 
profiles in non-malignant and matched cancer tissue from patients with CHB or CHC and 
associated HCC.  This study represents only the second sequencing-based profiling of miRNAs 
in chronic viral hepatitis.  We report four major findings.  First, we established that cholesterol 
synthesis and metabolism pathways are among the most dominantly altered in each of the 
disease states, particularly HCC.  Second, we defined for each disease state distinct liver 
miRNA signatures that included miRNAs not previously associated with viral hepatitis.  Third, 
we identified by integrative analysis of small RNA and mRNA expression data a suite of 
miRNAs that represent candidate drivers of the altered cholesterol pathways in chronic viral 
hepatitis.  Fourth, we validated through cell-based assays that miR-27, which is prominently 
dysregulated in both CHB and CHC as well as in HCC, significantly represses cholesterol 
synthesis in part through regulation of the gene that codes for the rate-limiting enzyme HMG-
CoA-Reductase (HMGCR).  
 
2.3 Results 
 
2.3a Pathways mediating cholesterol homeostasis are prominently altered in chronic 
viral hepatitis and liver cancer 
We interrogated previously described gene expression microarray data sets from 
matched cancer and non-cancer liver tissue collected from Japanese adults with chronic 
hepatitis B (CHB, n=10) or hepatitis C (CHC, n=16) and HCC (c-CHB, n= 10; c-CHC, n=16) as 
well as uninfected controls (n=9) (Supplemental Table S2.1)16,45. Correlation analyses of gene 
expression profiles showed that all samples within each disease category were highly correlated 
with each other (Fig. 2.1A), although the cancer samples were less strongly correlated (c-CHB 
median pairwise r2 = 0.86, c-CHC median pairwise r2 = 0.88) than the non-malignant CHB and 
CHC samples (median pairwise r2 = 0.96 and r2 = 0.95, respectively). 
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We then repeated this analysis using publically available RNA-sequencing data from 
The Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga/) for 18 c-CHB and 6 
matched CHB as well as 18 c-CHC and 5 matched CHC. We again found that the cancer 
samples were more poorly correlated (c-CHB median pairwise r2 = 0.58, c-CHC median pairwise 
r2 = 0.70) with each other compared to the non-cancer samples (median pairwise r2 = 0.98) (Fig. 
2.1B). The weaker pairwise correlations among c-CHB and c-CHC samples in the TCGA cohort 
compared to the microarray cohort may be due at least in part to the much higher dynamic 
range of expression provided by deep sequencing relative to microarray46, as well as increased 
genetic heterogeneity (due to representation from several different ancestries) among 
individuals in the TCGA cohort relative to the Japanese cohort. 
Next, using the microarray data from the Japanese cohort, we identified genes that were 
significantly differentially expressed (DE) in each of the four disease categories compared to the 
uninfected controls. We found that CHB and c-CHB had twice as many DE genes than CHC 
and c-CHC, respectively (Fig. 2.1C). Also, c-CHB and c-CHC had ~3-fold more DE genes than 
their non-malignant counterparts (Fig. 2.1C). For both CHB and CHC, 60% of DE genes were 
also significantly altered in the matched cancer samples (Fig. 2.1D). While only 17% of DE 
genes in CHC were also shared with CHB, 82% of DE genes in c-CHC were shared with c-CHB 
(Fig. 2.1D). 
To determine the pathways that are most affected in each disease category, we 
performed Ingenuity Pathway Analysis (IPA). We found that the DE genes in CHB and CHC 
were most significantly over-represented in distinct immune response pathways (Table 2.1A). 
For genes uniquely DE in CHB, the most enriched pathway was CD28 signaling, which is critical 
for T-cell activation and the production of interleukins47. For genes uniquely DE in CHC, the 
most enriched pathway was interferon signaling, which is critical to innate immunity48. For genes 
DE in both CHB and CHC, the most enriched pathways were related to lipid metabolism, 
including LXR/RXR activation, which plays a central role in cholesterol homeostasis49-51. Lipid-
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related pathways were even more prevalent among the DE genes in c-CHB and c-CHC (Table 
2.1B). For both CHB and CHC, the top three most significantly affected pathways were related 
to the function of RXR, which together with LXR and FXR regulates cholesterol balance. For 
genes DE in both c-CHB and c-CHC, another significantly enriched pathway was Aryl 
Hydrocarbon Receptor (AHR) signaling, which is involved in the suppression of hepatic 
cholesterol synthesis52. Indeed, we found that many of the genes that code for enzymes in the 
cholesterol synthesis pathway were down-regulated in all disease categories compared to 
uninfected controls (Fig. 2.2). 
 
2.3b Small RNA transcriptome analysis identifies novel differentially expressed 
microRNAs in chronic viral hepatitis and liver cancer 
Next we performed small RNA-sequencing in four liver samples from each of the 
disease categories in the Japanese cohort (uninfected controls, CHB, c-CHB, CHC, and c-
CHC). Seven out of the 8 c-CHB and c-CHC samples were matched with their corresponding 
non-malignant samples. We obtained an average of ~18 million reads from each, of which 
~70% mapped to the genome. miRNAs and their isomiRs were annotated and quantified by our 
previously described small RNA-seq analysis pipeline (Methods). Within category correlation 
analyses of miRNA expression profiles showed that uninfected controls were highly correlated 
(median pairwise r2 = 0.98), and as in the case of gene expression (Fig. 2.1A, B), the c-CHB 
samples were the most poorly correlated (median pairwise r2 = 0.70) (Fig. 2.3A). 
We repeated this analysis using publically available small RNA-sequencing data from 
TCGA (https://tcga-data.nci.nih.gov/tcga/) for 12 c-CHB and 6 matched CHB as well as 18 c-
CHC and 5 matched CHC. These patients represent a subset of the individuals for whom RNA-
seq data was available and analyzed (Fig. 2.1B). We quantified miRNAs according to our 
previously described small RNA-seq analysis pipeline53, and confirmed that the cancer samples 
were more poorly correlated (c-CHB median pairwise r2 = 0.83, c-CHC median pairwise r2 = 
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0.79) with each other compared to the non-cancer samples (median pairwise r2 > 0.95) (Fig. 
2.3B). 
Next, using the small RNA-seq data from the Japanese cohort, we identified DE miRNAs 
in each of the disease categories compared to the uninfected controls (Methods). The cancer 
samples (c-CHB and c-CHC) had a greater number of DE miRNAs than the non-cancer 
samples (CHB and CHC) (Fig. 2.3C).  Among the cancer samples, c-CHB had the greatest 
number of DE miRNAs (Fig. 2.3C). For each of CHB and CHC, ~60% of DE miRNAs were also 
significantly altered in the matched cancer samples (Fig. 2.3D). While only 35% of DE miRNAs 
in CHC were also shared with CHB, 67% of the DE miRNAs in c-CHC were shared with those in 
c-CHB (Fig. 2.3D). 
Figure 2.4 shows all 134 miRNAs that were DE in at least one disease category 
compared to uninfected controls. Eleven of the 134 (miR-378a-3p, miR-486-5p, miR-148a-3p, 
miR-148a-5p, miR-27a-3p, miR-146b-5p, miR-21-3p, miR-99b, miR-221, and miR-224) were DE 
in all four disease categories compared to the uninfected controls. Several of these, including 
miR-378a-3p and miR-27a-3p, have been associated previously with cholesterol homeostasis34. 
Using an automated PubMed literature search (Methods), we determined that among the 
miRNAs that were DE in at least one disease category, the one most studied in hepatitis and 
associated liver disease is miR-122 (Fig. 2.4), which has also previously been shown to 
influence lipid metabolism37. Although miR-122-5p, which promotes HCV replication38, did not 
satisfy our criteria for differential expression, miR-122-3p was significantly decreased in CHB, c-
CHB, and CHC (Fig. 2.4). While miR-122-3p is relatively understudied compared to miR-122-5p, 
we found that it was robustly expressed in all of the liver tissue samples (Supplemental Fig. 
2.1). We also found that miR-122-3p co-immunopurifies with Argonaute 2 (AGO2) in extracts 
from human hepatoma cells (FT3-7)16 and that its abundance in AGO2 immunoprecipitates is 
proportional to total intracellular levels, indicating efficient loading (Supplemental Fig. 2.1). 
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These data suggest that despite the extensive focus in the literature on miR-122-5p, miR-122-
3p is likely also a functional miRNA and merits further detailed experimental investigation. 
We identified several previously reported DE miRNAs, including miR-2154, miR-2755, and 
miR-18156 in CHC; miR-19957, miR-14858, and miR-12559 in CHB; and miR-221/22260, miR-
10161, and miR-22462 in chronic viral hepatitis associated liver cancer. Many of the other DE 
miRNAs that we identified, such as miR-215 and miR-340 in CHB; miR-1307 and miR-484 in 
CHC; and miR-136-5p and miR-3591-5p in c-CHC, have not been well studied in the liver. All of 
these miRNAs represent candidate regulators of the pathways altered in chronic viral hepatitis 
and liver cancer, including those governing cholesterol synthesis and metabolism. 
 
2.3c Several microRNAs are identified as candidate master regulators of pathways 
mediating cholesterol homeostasis in chronic viral hepatitis and liver cancer 
We next sought to identify DE miRNAs that represent potential key control points 
(master regulators) in the networks that regulate gene expression in chronic viral hepatitis and 
cancer. Using our previously developed tool miRHub (Methods), we identified 21 candidate 
master miRNA regulators of genes down-regulated in at least one disease group: CHB, c-CHB, 
CHC, or c-CHC (Fig. 2.5A). Among these 21, six were predicted to be master regulators in at 
least two different disease categories: miR-33, miR-199-3p, miR-194, miR-450b, miR-23, and 
miR-27-3p (Fig. 2.5A). miR-33, miR-199-3p, miR-450b, and miR-27-3p were significantly up-
regulated in c-CHB and c-CHC (Fig. 2.4) and identified as potential master regulators of down-
regulated genes in the same disease categories (Fig. 2.5A). Although hepatic miR-33 is a 
known regulator of cholesterol homeostasis, it has only recently been studied in the context of 
chronic viral hepatitis and HCC63. Both miR-199-3p and miR-27-3p are among the few miRNAs 
that have been reported as regulators of phenotypes associated with chronic viral hepatitis 
(cancer64 and dyslipidemia65,66, respectively). miR-194 and miR-23 were significantly down-
regulated in the same disease categories for which they were predicted as master regulators of 
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down-regulated genes. This finding is suggestive of transcriptional co-regulation of miR-
194/miR-23 and their target genes, consistent with the participation of these miRNAs in complex 
regulatory motifs67.  
We also identified 8 candidate master miRNA regulators of up-regulated genes in at 
least one of the disease categories (Fig. 2.5B). Interestingly, all 8 miRNAs were significantly up-
regulated in the same disease categories for which they were predicted to be master regulators 
of up-regulated genes. As with miR-194 and miR-23, one possible explanation for this finding is 
the widespread use of incoherent feed-forward miRNA loops in liver gene regulatory networks67. 
The strongest candidate master miRNA regulators in any disease category were miR-21 
and miR-33, which were both up-regulated in c-CHB (Fig. 2.4), and predicted to exert greater 
control of down-regulated genes in c-CHB than any other miRNA (Fig. 2.5A). miR-21 has been 
reported previously as a critical mediator of c-CHB and suppressor of the host immune system 
in CHC54. miR-33 is a key regulator of cholesterol homeostasis and has recently been 
associated with hepatic steatosis and fibrosis in patients with CHC and CHB, respectively63. 
For each miRNA predicted as a candidate master regulator of up- or down-regulated 
genes in each disease category, we identified biological pathways significantly enriched among 
its predicted target genes. We found that most candidate master regulator miRNAs were 
predicted to target genes over-represented in pathways regulating lipid homeostasis. For 
example, among down-regulated genes in c-CHB, 12 of the 13 candidate master miRNA 
regulators were predicted to target genes significantly over-represented in the PPARα/RXRα 
activation pathway. Several of these 12, including miR-21 and miR-33, have been recently 
reported as direct modulators of PPARα expression68 and miR-27-3p has been shown to target 
and repress both PPARα68 and RXRα69. Transcriptional regulation by PPARα/RXRα contributes 
to hepatic control of lipid biosynthesis70,71. These findings suggest that miRNAs are likely critical 
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in regulating cholesterol synthesis pathways in chronic viral hepatitis and associated liver 
cancer. 
 
2.3d miR-27 suppresses cholesterol synthesis via regulation of the rate-limiting enzyme, 
HMG-CoA-Reductase 
To evaluate whether the DE miRNAs contribute to the regulation of cholesterol 
synthesis, we selected miR-21, miR-27, and miR-224 for functional follow-up analyses. 
Specifically, we over-expressed each miRNA separately in human hepatoma cells (Huh7) grown 
in lipoprotein-deficient serum and evaluated the effect on de novo cholesterol synthesis 
(Methods). We found that all three DE miRNAs, but not a control miRNA (miR-151), suppressed 
cholesterol synthesis (Fig. 2.6A). Interestingly, all three of these miRNAs have at least one 
predicted seed sequence target site in the 3’ UTR of the HMG-CoA Reductase (HMGCR) gene 
(Fig. 2.6B), which encodes the rate-limiting enzyme in the cholesterol synthesis pathway. The 
predicted target sites for miR-27 and miR-224 are conserved across several mammalian 
species, whereas the predicted site for miR-21 is human-specific (Fig. 2.6B).  
 HMGCR mRNA was significantly decreased in all four disease categories, whereas miR-
27 and miR-224 were significantly elevated in all four disease categories, and miR-21 was 
increased in c-CHB and CHC (Fig. 2.6C). We have previously shown that miR-27 represses 
HMGCR expression65. To determine whether miR-27 may regulate HMGCR directly by targeting 
its 3’ UTR, we mined a published database (http://ago.rockefeller.edu) of results from a high-
throughput assay (AGO cross linking and immunoprecipitation followed by high-throughput 
sequencing, or AGO-CLIP-seq) that identified miRNA target sites across the transcriptome in 
P13 mouse brain, which expresses both miR-27 and HMGCR mRNA. We found evidence for 
AGO binding at the predicted miR-27 site, but not at the predicted sites for miR-21 (explained by 
the fact that this site is human-specific) or miR-224 (confounded by lack of robust miR-224 
expression in P13 mouse brain). To further evaluate the miR-27 binding site, we performed a 3’ 
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UTR reporter gene assay. Specifically, the entire HMGCR 3’UTR was PCR-amplified from 
human genomic DNA and cloned into the PsiCheck2 expression vector, downstream of the 
Renilla Luciferase [RL] coding region (Methods). The recombinant PsiCheck2 vector was then 
transfected into HEK293T cells and relative RL activity was measured in the absence and 
presence of oligonucleotide mimics of miR-27 or miR-375 (negative control). The miR-27 mimic 
induced significant repression (Fig. 2.6D), whereas miR-375 had no effect. We then introduced 
a mutation in the miR-27 target site via site-directed mutagenesis and demonstrated a partial 
but still significant (p < 0.01) rescue of relative RL activity. 
 
2.3e Model of miRNA-mediated regulation of cholesterol metabolism in chronic viral 
hepatitis and associated HCC 
At least nine genes in the cholesterol synthesis pathway were significantly down-
regulated in at least one disease category.  Of these nine, four of the genes (HMGCS1, 
HMGCR, DHCR24, and SC5DL) have evolutionarily conserved predicted target sites for ≥2 
miRNAs that are up-regulated more than 5-fold in at least one disease category and/or identified 
as master regulators of gene expression in at least one disease category (Fig. 2.7).  Predicted 
target sites for miR-499 and miR-224 are shared among two of the genes (HMGCS1/HMGCR 
and HMGCR/SC5DL, respectively) and three genes (HMGCS1, HMGCR, and SC5DL) harbor 
putative target sites for miR-27.  These three miRNAs represent key direct regulators of the 
cholesterol synthesis pathway in chronic viral hepatitis and associated liver cancer. 
The LXR/RXR regulatory pathway is significantly enriched among dysregulated genes in 
many of the disease groups (Table 2.1). This pathway is involved in the control of several 
aspects of cholesterol metabolism, most notably cholesterol efflux (Fig. 2.8). Numerous genes 
in the cholesterol efflux and transport pathway are significantly down-regulated in at least one 
disease state, including ABCA1, also known as cholesterol efflux regulatory protein (CERP), 
which is a direct target of LXR/RXR and is significantly decreased in expression in c-CHB and c-
	  	   17 
CHC. ABCA1 is predicted to be a target gene of 15 miRNAs that are up-regulated in at least 
one of c-CHB or c-CHC, including miR-33 and miR-27, which are established regulators of 
cholesterol efflux through suppression of ABCA166,72. 
 
2.4 Discussion 
Based on gene expression microarray data, we found pathways relating to cholesterol 
synthesis and metabolism to be the most significantly enriched among genes dysregulated in 
the various disease states we studied, especially c-CHB and c-CHC. Interestingly, in the non-
cancer samples, although immune pathways were the most significantly enriched, the specific 
immune pathways were different for CHB and CHC, which is consistent with distinct 
inflammatory features and innate immune responses in each disease. The top enriched immune 
pathway for CHC is interferon signaling and for CHB the top pathways are associated with both 
the innate and the adaptive immune response, although not interferon signaling. Some 
pathways, such as those controlling blood flow and coagulation (c-CHB and c-CHC), as well as 
amino acid degradation (c-CHB), merit future investigation. 
Studies of miRNAs in hepatitis C have been dominated by miR-122-5p, and only a few 
other miRNAs have been investigated. miR-122-5p was previously found to be reduced in 
patients with chronic hepatitis C, but the reduction was dependent on the IL28B genotype20. In 
this study, we performed small RNA-seq on two subjects from each IL28B genotype class (T/T 
and T/G, based on SNP rs8099917). Similar to what was reported previously20, miR-122 levels 
were reduced only in the individuals with the T/G genotypes and not the T/T genotype. Because 
our criteria for DE stipulated that the levels of a miRNA must change significantly and in the 
same direction in 3 out of the 4 samples in a disease group, miR-122-5p was not deemed to be 
DE in our study. 
Our study points to the potential functional relevance of miR-122-3p, which has received 
substantially less attention due to its lower expression than miR-122-5p. But we find that its 
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expression is robust and that it is effectively loaded and abundantly present on AGO2. miR-122-
3p was not a predicted miRNA master regulator of gene expression in any of the disease states, 
but it does have several key predicted mRNA targets, including the interferon stimulated gene, 
interferon induced protein with tetratricopeptide repeats 3 (IFIT3). We also show that a suite of 
other miRNAs, including miR-27, miR-33, miR-21, and miR-199, are significantly differentially 
expressed in one or more of the disease states and also are predicted to be master regulators 
of the disease gene expression profiles. 
We showed that several of these “master regulator” miRNAs, notably miR-33, miR-21 
and miR-27, are strongly associated with liver programs that control cholesterol homeostasis. 
Since miR-33 is already well-established as a modulator of cholesterol metabolism, we focused 
our functional studies on miR-27 and miR-21, as well as miR-224, which was among the most 
highly up-regulated in all disease states. miR-27 and miR-21 both significantly suppressed de 
novo cholesterol synthesis in Huh7 cells by ~30% and ~70%, respectively. We demonstrated 
that the effect of miR-27 is likely mediated in part through direct regulation of the gene HMGCR, 
which encodes the rate-limiting enzyme in cholesterol biosynthesis. Very few studies have 
linked miRNAs to the direct regulation of HMGCR. Both miR-27 and miR-21 may be candidate 
therapeutic targets for hypercholesterolemia. 
We found that the LXR/RXR pathway was prominently dysregulated in all disease 
states. This nuclear receptor pathway has known functions in the regulation of both lipid 
metabolism as well as immune and inflammatory responses. For example, recent in vivo studies 
have shown that LXR activation promotes cholesterol efflux and inhibits inflammation in part by 
suppressing NF-kB signaling73-75. In most of the disease states we studied, well-established 
LXR target genes such as CYP7A1 and ABCA1 were down-regulated, whereas genes 
promoted by NF-kB signaling were up-regulated (Table 2.1A). More detailed analysis is required 
to determine the role of miRNAs in controlling LXR/RXR in vivo during chronic viral hepatitis and 
thereby integrating lipid metabolic and inflammatory signaling. 
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CHB, CHC, and HCC have all been linked to cholesterol and lipid imbalance; however, 
the mechanisms have been poorly understood. Through integrative analysis of small RNA-seq 
and mRNA-seq data, and follow-up functional experiments in a cell-based system, our study 
provides important clues about the candidate miRNA drivers of this phenotype. Future 
investigations should focus on more detailed functional characterization of specific miRNAs of 
interest and their roles in regulating cholesterol homeostasis, particularly in the background of 
cirrhosis and the chronic inflammation present in viral hepatitis. As the use of locked nucleic 
acid (LNA) inhibitors expand, such studies may lead to the development of novel and effective 
miRNA-based therapeutic strategies. 
 
2.5 Materials and methods 
Human subjects. Written informed consent was obtained from all human subjects. 
Ethics approval was obtained from the Ethics Committee for Human Genome/Gene Analysis 
Research at Kanazawa University Graduate School of Medical Science.  
Gene expression analysis. Gene expression microarray data16,45 for CHB, CHB-c, 
CHC, and CHC-c were contrasted to the uninfected samples to determine differentially 
expressed (DE) genes (p-value < 0.05 after Benjamini-Hochberg step-up multiple testing 
correction and fold change > 2 compared to the uninfected samples) using Partek (Partek Inc.; 
St. Louis, MO). Pathway enrichment was determined with Ingenuity Pathway Analysis software 
(Qiagen; Hilden, Germany). 
Small RNA-sequencing. RNA was isolated as described previously16. RNA purity was 
assessed with Nanodrop 2000 (Thermo Scientific; Rockford, IL) and integrity was determined 
with an Agilent 2100 Bioanalyzer (Agilent; Santa Clara, CA). RNA integrity and sequencing 
quality were comparable for all specimens. Small RNA libraries were generated using Illumina 
TruSeq Small RNA Sample Preparation Kit (Illumina; San Diego, CA). Sequencing was 
performed on the Illumina HiSeq 2000 platform. Sequencing reads were trimmed using 
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Cutadapt (parameters O -10 e 0.1). Trimmed reads were mapped to genomic regions spanning 
annotated miRNAs (+/- 20 nts) using Bowtie 0.12.7 allowing for no mismatches. Next, reads that 
did not map without mismatches were aligned to the same regions using SHRiMP2.2.2. 
SHRiMP2.2.2 seeds were set based on the length of the read allowing 1 mismatch anywhere in 
the body and up to 3 mismatches at the 3' end of the read (based on the length of the read). 
Small RNA-sequencing data was deposited in GEO (GSE57381). TCGA liver cancer small 
RNA-seq BAM files annotated as having a risk factor of either “hepatitis B” or “hepatitis C” and 
no other annotated risk were downloaded and processed using the bioinformatics method 
described above. 
Automated PubMed searches. Automated search of PubMed using a Ruby program 
with the HTML parser Nokogiri on December 5, 2014. Search terms for the miRNAs: (“miRNA-
X” or “miR-X” or “microRNA-X”) with or without the miRNA family letter (e.g., miR-148a: 
(“miRNA-148a” or “miR-148a” or “microRNA-148a” or “miRNA-148” or “miR-148” or “microRNA-
148”)). Other search terms (search term: “liver”), HBV (search terms: “hepatitis B” or “HBV”), 
HCV (search terms: “hepatitis C” or “HCV”), or hepatocellular carcinoma (search terms: “HCC” 
or “hepatocellular” or “liver cancer”). 
Identification of miRNA candidate master regulators using miRHub. To identify 
miRNA candidate master regulators, we used the tool miRHub as described previously53. We 
predicted the miRNA master regulators for 8 different gene lists (significantly DE up-regulated 
genes in each disease group as well as significantly DE down-regulated genes in each), using 4 
different miRNA lists (DE miRNAs in each disease category irrespective of their fold change 
direction).  
Measuring cholesterol synthesis. Human hepatoma cells (Huh7) were seeded into 6-
well plates at a density of 1x105 cells/mL. After overnight growth, cells were transfected with 
miR-151 mimic or miR-21 mimic or miR-27 mimic or miR-224 mimic at 10nM each (Exiqon; 
Woburn, MA), or Lipofectamine 2000 transfection reagent only (mock; Life Technologies; Grand 
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Island, NY). Forty-eight hours after transfection, media was removed and replaced with DMEM 
low glucose lipoprotein deficient serum (LPDS) media. Seventeen hours later, low glucose 
media was removed and replaced with fresh serum-free low glucose media (cholesterol free) 
with 1uCi3H-acetic acid per well (0.5uCi/ml media) and incubated for 6 hours. Cells were 
washed twice with 1X Phosphate Buffered Saline. Two mL 3:2 hexane:isopropanol were added 
to each well; the cells were allowed to sit for 2 hours then placed in glass vials. Samples were 
dried down under nitrogen and 30µl of cold 0.1µg cholesterol:cholesteryloleate was added. 
Thirty µl of resuspended lipids were placed onto a plate and thin layer chromatography was 
performed (petroleum ether:diethyl ether:acetic acid). Spots were resolved with iodine, and 
cholesteryl ester, cholesterol and triglyceride spots were cut out and placed in 10mL scintillation 
fluid. Total protein for each well was quantified using the BCA assay. 
miRNA over-expression and reporter gene assays. HEK293T cells were maintained 
in 25mM glucose DMEM (Sigma-Aldrich; St. Louis, MO) supplemented with 10% FBS and 2mM 
L-glutamine (Invitrogen; Grand Island, NY), and cultured in a humidified incubator at 37oC and 
5% CO2.  HEK293T cells were seeded into 24 well plates and allowed to grow overnight. Once 
the cells were approximately 70% confluent, they were transfected with 200ng of pEZX-MT01 
empty vector, vector containing the 3’UTR of HMGCR (GeneCopoeia; Rockville, MD) and 10nM 
miRIDIAN microRNA hsa-miR-27b mimic (5’ UAGCACCAUCUGAAAUCGGUUA 3’, 
Dharmacon; Lafayette, CO) or 10 nM miRIDIAN microRNA hsa-miR-375 mimic (5’ 
UUUGUUCGUUCGGCUCGCGUGA 3’). Transfection was performed using Lipofectamine 2000 
(Life Technologies; Grand Island, NY). After 48 hours, the cells were lysed and luciferase 
activity was measured using the Luc-Pair luciferase assay kit (Agilent; Santa Clara, CA) on a 
GloMax® 96 Microplate Luminometer (Promega; Madison, WI). Site-directed mutagenesis was 
performed with the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent; Santa Clara, CA). 
Statistics and graphics. P-values were calculated and plots were generated using R 
and Prism. Proportional Venn diagrams were generated by the R package “VennDiagram”. 
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Table 2.1. Results of pathway enrichment analysis of chronic viral hepatitis and cancer. 
(A & B) Top ten most significantly enriched pathways from Ingenuity Pathway Analysis using 
either all differentially expressed (DE) genes of a disease group (“all”), DE genes of a disease 
group with no overlap with any other group (“only”), or DE genes shared between two disease 
groups (“overlap”). (A) Pathway analysis for CHB and CHC. (B) Pathway analysis for c-CHB 
and c-CHC. 
 
Table 2.1A 
 
CHB all CHB only CHB and CHC overlap CHC all CHC only 
Signaling by Rho 
Family GTPases 
(3.55E04) 
CD28 Signaling 
in T Helper Cells 
(1.05E-04) 
Phosphatidylchol
ine Biosynthesis 
(1.02E-03) 
Phosphatidylchol
ine Biosynthesis 
(1.86E-06) 
Interferon 
Signaling 
(4.68E-07) 
Natural Killer 
Cell Signaling 
(3.63E-04) 
Tec Kinase 
Signaling (1.7E-
04) 
Choline 
Biosynthesis 
(3.72E-03) 
Interferon 
Signaling 
(1.66E-05) 
Pathogenesis of 
Multiple 
Sclerosis (4.57E-
05) 
Role of PRRs 
(4.47E-04) 
Signaling by Rho 
Family GTPases 
(2.00E-04) 
Polyamine 
Regulation in 
Colon Cell 
prolif/cancer 
(1.05E-02) 
Pathogenesis of 
Multiple 
Sclerosis (2.82E-
04) 
iNOS Signaling 
(4.79E-04) 
CD28 Signaling 
in T Helper Cells 
(7.08E-04) 
Natural Killer 
Cell Signaling 
(2.09E-04) 
Epoxysqualene 
Biosynthesis 
(1.41E-02) 
Choline 
Biosynthesis 
(9.2E04) 
Phosphatidylchol
ine Biosynthesis 
(1.41E-03) 
CXCR4 
Signaling 
(9.12E-04) 
CTLA4 Signaling 
in Cytotoxic T 
Lymphocytes 
(5.0E-04) 
Toll-like 
Receptor 
Signaling 
(1.58E-02) 
Type I Diabetes 
Mellitus 
Signaling 
(1.58E03) 
Type I Diabetes 
Mellitus 
Signaling 
(2.24E-03) 
Integrin 
Signaling 
(1.00E-03) 
MSP-RON 
Signaling 
Pathway 
(6.04E-04) 
TREM1 
Signaling 
(1.62E-02) 
iNOS Signaling 
(4.57E03) 
Phosphatidyleth
anolamine 
Biosynthesis 
(2.34E-03) 
NF- κB 
Signaling 
(1.26E-03) 
Renin-
Angiotensin 
Signaling 
(7.41E-04) 
PRPP 
Biosynthesis 
(2.14E-02) 
Phosphatidyleth
anolamine 
Biosynthesis 
(7.94E03) 
Prolactin 
Signaling 
(3.16E-03) 
Tec Kinase 
Signaling 
(1.35E-03) 
PRRs of 
Bacteria and 
Viruses 
(7.76E-04) 
Arsenate 
Detoxification 
(2.82E-02) 
LXR/RXR 
Activation 
(1.12E02) 
B Cell Receptor 
Signaling 
(3.55E-03) 
Dendritic Cell 
Maturation 
(1.82E-03) 
Integrin 
Signaling 
(8.13E-04) 
Tetrahydrofolate 
(3.47E-02) 
Hepatic Fibrosis 
/ Hepatic Stellate 
Cell Activation 
(0.01) 
Antigen 
Presentation 
Pathway 
(3.55E-03) 
MSP-RON 
Signaling 
Pathway 
(1.91E-03) 
CXCR4 
Signaling 
(1.23E-03) 
LXR/RXR 
Activation (5.5E-
02) 
Comm. between 
Innate and 
Adaptive 
Immune Cells 
(0.013) 
PDGF Signaling 
(3.89E-03) 
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Table 2.1B 
c-CHB all c-CHB only c-CHB and c-CHC overlap c-CHC all c-CHC only 
FXR/RXR 
Activation 
(1.00E-23) 
FXR/RXR 
Activation (2.00 
E-14) 
LXR/RXR 
Activation (1.1E-
08) 
LXR/RXR 
Activation (4.27E-
09) 
Pathogenesis of 
Multiple 
Sclerosis (7.94 
E-05) 
LPS/IL-1 
Mediated 
Inhibition of RXR 
Function  
(2.51 E-18) 
LPS/IL-1 
Mediated 
Inhibition of RXR 
Function  
(2.95 E-10) 
FXR/RXR 
Activation 
(2.88E-08) 
LPS/IL-1 Mediated 
Inhibition of RXR 
Function  
(1.20E-07) 
Cell Cycle: G1/S 
Checkpoint 
Regulation  
(3.89E-03) 
LXR/RXR 
Activation (2.51 
E-16) 
Acute Phase 
Response 
Signaling (3.72 
E-10) 
LPS/IL-1 
Mediated 
Inhibition of RXR 
Function  
(5.25E-08) 
FXR/RXR 
Activation (8.71E-
07) 
Protein Kinase A 
Signaling 
(5.50 E-03) 
Acute Phase 
Response 
Signaling (1.58 
E-12) 
LXR/RXR 
Activation (1.02 
E-07) 
Chemokine 
Signaling (1.17E-
04) 
Complement 
System (7.41E-05) 
Small Cell Lung 
Cancer Signaling 
(5.62 E-03) 
Blood 
flow/coagulation 
System  
(3.31E-09) 
Intrinsic 
Prothrombin 
Activation 
Pathway (6.17 E-
07) 
Aryl Hydrocarbon 
Receptor 
Signaling (3.55E-
04) 
Phosphatidylcholine 
Biosynthesis 
(3.31 E-04) 
Cyclins and Cell 
Cycle Regulation 
(7.76 E-03) 
Intrinsic 
Prothrombin 
Activation 
Pathway (4.27E-
08) 
Extrinsic 
Prothrombin 
Activation 
Pathway (6.46 E-
07) 
Fatty Acid α-
oxidation 
(6.76E-04) 
Hepatic Cholestasis 
(4.07 E-04) 
RAR Activation 
(8.71 E-03) 
Complement 
System (6.31E-
08) 
Phenylalanine 
Degradation 
(2.34 E-06) 
Dopamine 
Degradation 
(7.24 E-04) 
Aryl Hydrocarbon 
Receptor Signaling 
(4.27 E-04) 
Granulocyte 
Adhesion and 
Diapedesis 
(8.91 E-03) 
Estrogen 
Biosynthesis 
(7.94E-08) 
Blood 
flow/coagulation 
System 
(6.46 E-06) 
Atherosclerosis 
Signaling 
(7.41E-04) 
Bile Acid 
Biosynthesis, 
Neutral Pathway 
(5.50 E-04) 
Glioma Signaling 
(1.55 E-02) 
Xenobiotic 
Metabolism 
Signaling (1.02E-
07) 
Xenobiotic 
Metabolism 
Signaling (2.29 
E-05) 
Complement 
System (7.76E-
04) 
Chemokine 
Signaling (6.76 E-
04) 
Type I Diabetes 
Mellitus 
Signaling (2.45 
E-02) 
Valine 
Degradation 
(1.2E-07) 
Valine 
Degradation 
(2.63 E-05) 
Blood 
flow/coagulation 
System 
(1.12E-03) 
Blood 
flow/coagulation 
System 
(6.92 E-04) 
IL-17A Signaling 
in Gastric Cells 
(2.57 E-02) 
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Table S2.1 Clinical information of subjects assessed 
Clinical Information 
Subject ID Age Sex *METAVIR Tumor 
HBV 1 61 M F4A1 mHCC 
HBV 2 46 M F4A2 mHCC 
HBV 3 45 M F4A1 mHCC 
HBV 4 60 M F2A1 pHCC 
HBV 5 71 F F2A1 pHCC 
HBV 6 59 M F3A1 mHCC 
HBV 7 54 M F4A1 mHCC 
HBV 8 42 M F4A1 mHCC 
HBV 9 58 M F2A2 mHCC 
HBV 10 47 M F3A2 pHCC 
HCV 1 72 F F3A1 mHCC 
HCV 2 78 F F4A1 mHCC 
HCV 3 47 M F3A2 mHCC 
HCV 5 68 M F4A2 wHCC 
HCV 6 67 F F4A2 w-mHCC 
HCV 7 63 M F4A1 mHCC 
HCV 8 71 M F4A2 wHCC 
HCV 9 64 M F4A2 mHCC 
HCV 10 75 F F4A2 m-pHCC 
HCV 11 59 M F4A2 mHCC 
HCV 12 74 M F3A1 W-mHCC 
HCV 15 71 F F4A1 mHCC 
HCV 16 60 M F4A1 m-pHCC 
HCV 17 74 M F2A1 mHCC 
HCV 18 59 M F3A1 mHCC 
HCV 20 63 M F1A1 mHCC 
Uninfected 1 60 F N/A N/A 
Uninfected 2 51 F N/A N/A 
Uninfected 3 53 M N/A N/A 
Uninfected 4 34 M N/A N/A 
Uninfected 5 78 F N/A N/A 
Uninfected 6 78 M N/A N/A 
Uninfected 7 64 M N/A N/A 
Uninfected 8 75 M N/A N/A 
Uninfected 9 48 F N/A N/A 
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Figure 2.1 Global gene expression in chronic viral hepatitis and cancer. (A & B) Pearson 
correlation coefficient heat maps. Each cell in the map represents the correlation in expression 
profiles between two samples. Cells along the diagonal represent identical samples and are 
colored in white. Black lines divide each disease group. Midpoint for color bar r2 = 0.5. (A) Data 
from microarray analyses include only genes with average normalized expression of >1,000 
(n=8,162) in uninfected controls (n=9), CHB and matched c-CHB (n=10 each), and CHC and 
matched c-CHC (n=16 each). (B) The Cancer Genome Atlas RNA-seq data include genes with 
an average normalized read count > 50 (n=13,017) in each disease category: c-CHB (n=12), 
CHB (n=6), c-CHC (n=18), and CHC (n=5). (C & D) Analysis of differentially expressed (DE) 
genes in each disease category compared to the uninfected controls with a fold change > 2 and 
p-value <0.05 after Benjamini-Hochberg step-up multiple testing correction. (C) Number of DE 
genes. (D) Proportional Venn diagrams comparing the DE genes of the different disease 
groups.  
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Figure 2.2 Expression of genes in the cholesterol synthesis pathway in chronic viral 
hepatitis and cancer. Log2 of average fold change in each disease group (CHB, c-CHB, CHC, 
and c-CHC) compared to uninfected controls for genes that code for major enzymes within the 
cholesterol biosynthesis pathway. Due to decreasing reliability from “_at”, “_s_at”, to “_x_at”, for 
genes with multiple probe types, the most reliable annotations are displayed.  Results are 
shown for “_s_at” only if  “_at” were not available and for “_x_at” probes only if “_s_at” or “_at” 
probes were not available.   
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Figure 2.3 Global miRNA expression in chronic viral hepatitis and cancer. (A & B) 
Pearson correlation coefficient heat maps. Each cell in the map represents the correlation in 
expression profiles between two samples. Cells along the diagonal represent identical samples 
and are colored in white. Black lines divide each disease group. Midpoint for color bar r2 = 0.5. 
(A) miRNAs included are those from small RNA-sequencing with average reads per million 
mapped (RPMM) >100 (n=208) in uninfected controls (n=4), CHB (n=4), matched c-CHB (n=4), 
CHC (n=4), and matched c-CHC (n=4) samples. (B) miRNAs from The Cancer Genome Atlas 
small RNA-seq with an overall average RPMM > 100 (n=180) in each disease category: CHB 
(n=6), c-CHB (n=12), CHC (n=5), and c-CHC (n=15). (C & D) Analysis of differentially 
expressed (DE) miRNAs in each disease category compared to the uninfected controls 
including only miRNAs that have: (i) RPMM > 50, (ii) a fold change > 1.5, and (ii) changes in the 
same direction for at least 3 out of 4 samples from each disease group. 5’-shifted isomiRs 
(sequence variants of canonical miRNAs with a different seed sequence) are included in this 
analysis. (C) Number of DE miRNAs. (D) Proportional Venn diagrams comparing the DE 
miRNAs of different disease groups. 
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Figure 2.4 Published literature on miRNAs that are differentially expressed in chronic 
viral hepatitis and liver cancer.  (Left of each panel shown) Heat map of significantly 
differentially expressed miRNAs in each disease group (CHB, c-CHB, CHC, and c-CHC) 
compared to the uninfected controls that have: (i) an average fold change > 1.5 in one disease 
state, (ii) a change in the same direction in at least 3 out of 4 samples within each disease 
group, and (iii) reads per million mapped reads (RPMM) > 50 in at least one disease group. 
Color represents log2 (average fold change) compared to the uninfected controls. Black boxes 
indicate that the miRNA for a specific disease state did not fit the criteria of DE. (Center and 
right of each panel shown) Results of automated searches of PubMed on December 5, 2014 
using search terms for the miRNA: (“miRNA-X” or “miR-X” or “microRNA-X”) with or without the 
miRNA family letter (e.g., miR-148a: (“miRNA-148a” or “miR-148a” or “microRNA-148a” or 
“miRNA-148” or “miR-148” or “microRNA-148”)) and ignoring the “-3p” or “-5p”. (center) Number 
of total published papers indexed on PubMed based on searches of just the miRNA name. 
Color bar mid-point at 100. (right) Proportion of total published papers related to each miRNA 
that was associated with liver (search term: “liver”), HBV (search terms: “hepatitis B” or “HBV”), 
HCV (search terms, “hepatitis C” or “HCV”), or hepatocellular carcinoma (search terms: “HCC” 
or “hepatocellular” or “liver cancer”). 
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Figure 2.5 Candidate miRNA master regulators of gene expression profiles in chronic 
viral hepatitis and associated liver cancer. (A & B) Heat map of the –log10(p-value) of the 
predicted targeting score for each miRNA (determined using miRHub) among genes de-
regulated in each disease category (CHB, c-CHB, CHC, and c-CHC) compared to uninfected 
controls. Only miRNAs with p-value < 0.05 in at least one disease group are shown. Black 
boxes indicate that the miRNA for a specific disease state did not fit the criteria of DE. (A) 
Analysis of significantly down-regulated genes in each disease category. (B) Analysis of 
significantly up-regulated genes in each disease category. 
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Figure 2.6 Candidate miRNA master regulators miR-27 and miR-21 control cholesterol 
synthesis in vitro. (A) Human hepatoma (Huh7) cells transfected with either 10 nM of miRNA 
mimic or transfection reagent alone (mock): miR-151, mock (n=6) and mimic (n=3); siRNA, 
mock (n=6) and mimic (n=6); miR-27, mock (n=6) and mimic (n=6); miR-21, mock (n=6) and 
mimic (n=6); miR-224, mock (n=5) and mimic (n=5). De novo cholesterol synthesis measured 
by radiolabeled acetate incorporation assay (see Methods). Relative change compared to mock 
transfection is shown. (B) Predicted target sites in the HMGCR 3’ UTR for miR-27, miR-21, and 
miR-224 as determined by the TargetScan algorithm. (C) Relative levels of HMGCR mRNA, 
miR-21, miR-27, and miR-224 across the disease categories. Fold-change for HMGCR based 
on comparison to uninfected controls. RPMM, reads per million mapped reads. (D) Effects of 
miR-27 mimic (10 nM) and miR-375 (10 nM, negative control) on the activity of Renilla (RL) 
luciferase containing either wild-type or mutated HMGCR 3’ UTR normalized to Firefly luciferase 
(FL) in transfected Huh7 cells. Each condition was tested twice with three technical replicates 
each (total n=6). The mutation was targeted to the predicted miR-27 target site. P-values 
determined using two-tailed unpaired Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.005. 
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Figure 2.7 Model of miRNA regulation of cholesterol synthesis in chronic viral hepatitis 
and associated liver cancer. Cholesterol synthesis genes that are significantly altered in at 
least one disease state are shown. Pie shading to the right of each gene indicates the disease 
states in which each gene is significantly altered as defined previously (light pink: c-CHB, dark 
pink: CHB, light blue: c-CHC, dark blue: CHC). Green outline indicates that the gene is down-
regulated. Each of the miRNAs displayed have at least one predicted target site in at least one 
of the genes listed, which is conserved between human and at least one other species. Each 
miRNA is significantly up-regulated in at least one disease state relative to uninfected controls, 
and is either a predicted miRNA master regulator of gene expression in at least one disease 
state based on miRHub p-value < 0.05 (pie piece outlined in blue) or has a fold change > 5 
compared to uninfected controls (outlined in orange) or both (outlined in black).  
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Figure 2.8 Model of miRNA regulation of cholesterol transport and efflux in chronic viral 
hepatitis and associated cancer. Significantly altered cholesterol transport and efflux genes in 
at least one disease state are shown. Pie shading to the right of each gene indicates the 
disease states in which each gene is significantly altered as define previously (light pink: c-CHB, 
dark pink: CHB, light blue: c-CHC, dark blue: CHC). Green or red outline indicates that the gene 
is down-regulated or up-regulated, respectively. Each of the miRNAs displayed have at least 
one predicted target site, in at least one of the genes listed, which is conserved between human 
and at least one other species. Each miRNA is significantly up-regulated in at least one disease 
state relative to uninfected controls, and is either a predicted miRNA master regulator of gene 
expression in at least one disease state based on miRHub p-value < 0.05 (pie piece outlined in 
blue) or has a fold change > 5 compared to uninfected controls (outlined in orange) or both 
(outlined in black). 
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Supplemental Figure 2.1 miR-122-3p and miR-122-5p comparison. (A) Small RNA-
sequencing results from AGO2 immunoprecipitation and total RNA from FT3-7 cells for miR-
122-3p and miR-122-5p. (B) Small RNA-sequencing results for miR-122-3p and miR-122-5p in 
liver tissue from each of the disease states (uninfected control, CHB, c-CHB, CHC, and c-CHC). 
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CHAPTER 3 
 
Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic 
hepatitis B and C1 
 
3.1 Overview 
 
Persistent infections with HBV or HCV account for the majority of cases of hepatic 
cirrhosis and HCC worldwide. Small, non-coding RNAs play important roles in virus-host 
interactions. We used high throughput sequencing to conduct an unbiased profiling of small (14-
40 nts) RNAs in liver from Japanese subjects with advanced hepatitis B or C and HCC. Small 
RNAs derived from tRNAs, specifically 30-35 nucleotide-long 5’ tRNA-halves (5’ tRHs), were 
abundant in non-malignant liver and significantly increased in humans and chimpanzees with 
chronic viral hepatitis. 5’ tRH abundance exceeded microRNA abundance in most infected non-
cancerous tissues. In contrast, in matched cancer tissue, 5’ tRH abundance was reduced, and 
relative abundance of individual 5’ tRHs was altered. In hepatitis B-associated HCC, 5’ tRH 
abundance correlated with expression of the tRNA-cleaving ribonuclease, angiogenin. These 
results demonstrate that tRHs are the most abundant small RNAs in chronically infected liver 
and that their abundance is altered in liver cancer. 
 
3.2 Introduction 
 
HBV and HCV are phylogenetically unrelated non-cytopathic viruses that infect the liver1. 
While HBV is a DNA virus, and HCV is a positive-strand RNA virus, both have the capacity to 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This chapter previously appeared as an article in Scientific Reports. The original citation is as follows: 
Selitsky, S. R. et al. Small tRNA-derived RNAs are increased and more abundant than microRNAs in 
chronic hepatitis B and C. Scientific reports 5, 7675 (2015).	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persist for years in some infected individuals. Hundreds of millions of people worldwide are 
chronic carriers of HBV or HCV, 30-50% of whom have chronic liver disease2. Together, these 
viral infections are responsible for ~60% of liver cirrhosis and ~80% of HCC, a leading cause of 
cancer-related deaths worldwide. Numerous studies suggest that miRNAs, small 21-23 nt non-
coding RNAs are important in the pathogenesis of these infections, modulating viral replication 
as well as host responses and possibly influencing the risk of carcinogenesis3. For example the 
HBV X protein represses expression of miR-148a, potentially enhancing tumorigenesis4. In 
contrast, HCV infection is associated with higher expression of miR-21, which targets key 
components of Toll-like receptor signaling pathways, possibly facilitating viral evasion of innate 
immune responses5. miR-122 stabilizes HCV RNA and promotes its replication6,7, and the 
importance of this interaction is reflected in the clinical development of an anti-miR-122 
antagomir (miravirsen) as an antiviral therapeutic8.  
Somewhat larger, 30-35 nt RNAs derived from the 5’ half of tRNA (5’ tRHs) represent a 
second major class of small noncoding RNA9. Increased expression of 5’ tRHs has been 
associated with viral and rickettsial infections in animals10,11, and may serve to prevent 
apoptosis and promote cell survival12. However, they have not been studied previously in the 
context of viral hepatitis. To our knowledge, only one study has described unbiased profiling of 
small RNAs in the liver during chronic viral hepatitis13, but the analysis was restricted to 
miRNAs. We sequenced small (14-40 nts) RNAs in liver biopsies from subjects with chronic 
hepatitis and HCC, examining both non-tumor and matched cancer tissue, and found a 
surprisingly high proportion of reads representing 5’ tRHs9. Our results document their presence 
in human tissue, demonstrate that they are the most highly abundant small RNAs in virus-
infected liver, and show that their abundance is altered in various disease states including 
hepatocellular carcinoma. 
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3.3 Results 
 
3.3a tRNA-half abundance is significantly increased in chronic viral hepatitis  
 
We employed high-throughput sequencing to characterize the small RNA transcriptome 
in liver tissue from Japanese adults with advanced hepatitis B or hepatitis C and concomitant 
HCC (Table S2.1). Initial studies focused on non-malignant tissue from 4 subjects with hepatitis 
B (mean age 53 ± 4 yrs s.e.m.), 4 with hepatitis C (63 ± 2 yrs), and 4 uninfected individuals 
undergoing resection of metastatic tumors (60 ± 10 yrs)14. A large proportion of the sequencing 
reads were 19-25 nts in length (median 38%, range 10-73%), as expected for miRNAs15 (Figure 
3.1A, left). However, we detected an equal or greater abundance of 30-35 nt reads in HBV- and 
HCV-infected liver (median 54%, range 14-80%). These larger RNAs were less abundant in 
uninfected tissue (median 21%, range 14-84%) and in human hepatoma (FT3-7) cells (median 
9%, range 8.7-9.3%). 
Most (~65%) of the 30-35 nt reads in infected samples aligned perfectly to the region 5’ 
of the anticodon triplet in annotated tRNA genes16 (Figure 3.1B, Supplemental Figure 3.1). We 
refer to these as “5’ tRNA-halves” (5’ tRHs)9. Many of the remaining 30-35 nt reads also aligned 
to the 5’ end of tRNAs, particularly tRNAGly, but with one or more nucleotide deletions. Also 
present were 3’ tRHs (~36-39 nts) mapping to the region 3’ of the anticodon, including the 3’ 
terminal CCA (Figure 3.1B, Supplemental Figure 3.1). Additionally, we identified shorter reads 
derived from 3’ or 5’ tRNA termini, referred to previously as “tRNA fragments”9 (tRFs), or the 
region immediately 5’ or 3’ of the anticodon loop, but these were much less frequent. In 6 of 8 
infected livers, more reads mapped to tRNA loci16 than to known miRNAs17 (see Methods), 
while the opposite was true in 3 of 4 uninfected tissues as well as FT3-7 cells (Figure 3.1A, 
right). 
There are 625 annotated tRNA genes in the human genome (hg19) encoding 458 
unique tRNA sequences. We identified reads mapping to 348 of these 458 sequences. Notably, 
in 11 of the 12 subjects, the same five 5’ tRHs comprised >80% of tRNA-derived reads 
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(Supplemental Figure 3.2A). The two most abundant 5’ tRHs were Gly[C/G]CC (“5’ tRHGly”), 
which could be derived from any of 10 tRNAGly genes with identical 5’ sequence, and 
Val[A/C]AC (“5’ tRHVal”), which could originate from any of 15 tRNAVal genes (Figure 3.1B and C, 
Supplemental Figure 3.1 and 3.3)16. 5’ tRHGly accounted for 54 ± 9% (s.d.) and 5’ tRHVal 17 ± 9% 
of all tRNA-derived RNA reads (Supplemental Figure 3.2A). Remarkably, 5’ tRHGly abundance 
exceeded that of miR-122, one of the most abundant liver miRNAs13, in 7 of 8 virus-infected 
tissues. 
We used real-time reverse transcription quantitative PCR (RT-qPCR) to validate these 
results and compare 5’ tRHGly, 5’ tRHVal and miR-122 abundance in liver tissue from 22 
additional subjects14. These analyses confirmed that 5’ tRHGly abundance was increased in 
HBV- and HCV-infected liver compared with uninfected tissues (P<0.01 and P<0.05, 
respectively) (Figure 3.1D, left). A similar trend was observed for 5’ tRHVal (HBV P=0.07; HCV 
P=0.7). 5’ tRHGly and 5’ tRHVal were more abundant than miR-122 in HBV- and HCV-infected 
liver (5’ tRHGly, P<0.005 for both HBV and HCV; 5’ tRHVal, P<0.005 for HBV and P<0.01 for 
HCV) (Figure 3.1D left). Notably, 5’ tRHVal abundance was higher in HBV- than in HCV-infected 
tissues (P<0.005). 
Chimpanzees (Pan troglodytes) recapitulate many aspects of HBV and HCV infections in 
humans18,19, and are free of potential confounding variables (e.g., alcohol intake, smoking) that 
are difficult to control in human cohorts. Similar to humans, we found that intrahepatic 5’ tRHGly 
and 5’ tRHVal abundance was increased in archived liver tissue from chimpanzees chronically 
infected with HBV compared to uninfected animals (P<0.005 and P<0.05, respectively) (Figure 
3.1D, right). However, 5’ tRH abundance was not increased in chronically HCV-infected 
chimpanzee liver.  
In human tissues, the relative abundance of specific tRNA-derived RNAs correlated with 
codon usage (codon frequency in DNA sequence) (Spearman’s rho=0.32, P=0.01) and the 
number of possible tRNA genes from which each could originate (rho=0.41, P=0.001) 
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(Supplemental Figure 3.2B). However, tRNAs representing potential sources of the five most 
abundant tRHs were not the most highly ranked by gene number or codon usage, suggesting 
that additional factors likely determine tRH biogenesis (Supplemental Figure 3.4). Interestingly, 
those tRNAs from which 5’ tRHGly and 5’ tRHVal are potentially derived share a unique sequence 
motif in the stem-loop region (Figure 3.1E) not present in other tRNAs (Supplemental Figure 
3.3). 
 
3.3b tRNA-half abundance is altered in viral hepatitis associated cancer 
 
In HCC tissue from HBV-infected subjects, RT-qPCR analysis showed that 5’ tRHGly and 
5’ tRHVal abundance was significantly reduced (P<0.005 for both) (Figure 3.2A). Similar 
reductions were evident in HCV-associated cancer tissue, but significant only for 5’ tRHVal 
(P<0.05). We then sequenced small RNAs in cancer tissue from 4 HBV- and 4 HCV-infected 
subjects. The proportion of reads mapping to tRNA genes was reduced in 4 of 7 samples for 
which a paired analysis with non-malignant liver was possible, and relatively unchanged in the 
other 3 (Figure 3.2B). Although tRNA-derived RNA expression profiles were similar across non-
malignant tissues from different subjects, there was substantial variation when compared to 
cancer tissues (Figure 3.2C). This suggests that the relative abundance of specific tRNA-
derived RNAs is altered in HCC. Notably, the relative abundance of 5’ tRHGly was reduced by 
~50-60% in both HBV- and HCV-associated cancer (Figure 3.2D). 
 
3.3c tRNA-half abundance correlates with angiogenin levels in HBV-associated cancer 
 
Angiogenin (encoded by the gene ANG) is best known for its role in angiogenesis, but 
several studies suggest its RNase activity contributes to tRH biogenesis20,21. Consistent with 
this, analysis of previous microarray data obtained from these tissues14 revealed that ANG 
mRNA was reduced in both HBV- and HCV-associated cancer compared to non-malignant 
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tissue (P<0.01 and P<0.005, respectively) or uninfected liver (P<0.005 and P=0.01) (Figure 
3.3A). Analysis of data from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/) also 
indicates that ANG expression is reduced in HCC compared to non-malignant tissue, although 
the difference is significant only for HBV-associated cancer (HBV P<0.005, HCV P=0.12) 
(Supplemental Figure 3.5). ANG mRNA abundance correlated strongly with 5’ tRH expression in 
the HBV-infected subjects we studied (5’ tRHGly: Spearman’s rho=0.67, P<0.01; 5’ tRHVal: 
rho=0.74, P<0.005) (Figure 3.3B). Quantitative immunoblot analyses (Supplemental Figure 3.6) 
confirmed a correlation between ANG protein abundance and 5’ tRH expression in HBV-
associated cancer (5’ tRHGly: rho=0.83, P<0.005; 5’ tRHVal: rho=0.87, P<0.005) (Figure 3.3C). 
ANG was expressed within the cytoplasm of hepatocytes (Figure 3.3D), and although its 
expression varied substantially in different tumors (Figure 3.3E), reductions in ANG expression 
likely explain the reduced tRH abundance we observed in most HBV-associated cancers. 
Unfortunately, however, the available tissue sections from these subjects were insufficient to 
power a formal analysis of the correlation between cytoplasmic versus nuclear expression of 
ANG and tRH abundance. ANG expression correlated poorly with tRH abundance in HCV-
infected livers, suggesting that other factors determine tRH biogenesis.  
 
3.4 Discussion 
 
Recent advances in high-throughput sequencing technology have unveiled the 
complexity and diversity of functional small RNAs. We found that small RNAs derived from 
tRNAs, specifically 5’ tRNA-halves9 (5’ tRHs, ~30-35 nts), are abundant in liver, significantly 
increased during chronic viral infection, and altered in abundance in liver cancer associated with 
these infections. We do not believe that these tRNA-halves are products of stochastic 
endonuclease cleavage of tRNAs for several reasons. First, the same tRNA-halves were found 
to be increased in chronic viral hepatitis across all individuals. Second, each tRNA-half family 
exhibited a uniform length distribution (e.g., 5’ tRHGly was represented primarily by reads of 
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length 32-34 in every individual). Third, tRNA-halves were preferentially induced in chronic HBV 
infection (as compared to chronic HCV infection) in both human and chimpanzee tissue, 
indicating biological specificity. Finally, tRH abundance was correlated with disease state 
(cancer versus non-cancer), indicating reproducible sensitivity to the cellular environment. 
Several models of disease have been shown to exhibit an increase in tRH abundance, 
including cultured human airway cells infected with respiratory syncytial virus22, mice infected 
with spotted-fever group rickettsia23, and rats treated with cisplatin24. While their function is not 
well understood, previous work in cell culture suggests that some tRHs promote cell survival, 
are anti-apoptotic12, reduce translation25, and promote the formation of stress granules26. 
Preliminary studies in our laboratory do not support a role for 5’ tRHGly or 5’ tRHVal in the 
regulation of global protein translation in human hepatoma cells (Supplemental Figure 3.7-3.8); 
however, more detailed investigation is required to uncover the potential functions of tRHs. It 
has also been suggested that tRHs may alter the immune response due to their enrichment in 
mouse lymphoid organs27, high abundance in seminal exosomes (considered to be 
immunosuppressive)28, and roles in facilitating Trypanosoma cruzi infection in human cells and 
altering host gene expression29. 
There is good evidence that the abundance of these small non-coding RNAs increases 
in response to specific kinds of cellular stress. For example, tRHs are induced in cell culture by 
the addition of sodium arsenite, exposure to UV, nutrient starvation, hypoxia, hypothermia and 
heat, but not by exposure to etoposide, γ-radiation, caffeine30,31. This strongly suggests that the 
formation of tRHs is a regulated process, rather than due to general degradation of tRNAs in 
response to stress. In the nucleus angiogenin is involved in promoting angiogenesis32 and in the 
cytoplasm, when not bound to RNH1, it acts as a tRNA-processing RNase33,34, cleaving tRNAs 
at the anticodon loop and producing tRHs30,31. The cellular localization of angiogenin and its 
ribonuclease activity depend on the intracellular conditions and are regulated by RNH133. The 
differences we observed in correlations between ANG expression and tRH abundance in 
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chronic hepatitis B, hepatitis C and associated liver cancer may be a result of differences in 
angiogenin localization and function in these disease states. Non-tumor and tumor tissues from 
patients with chronic hepatitis C tend to show more evidence of angiogenesis than the in 
chronic hepatitis B35,36. This could mean that in chronic hepatitis C angiogenin is primarily 
nuclear, and therefore not exclusively involved in tRH production. Finally, it must also be noted 
that factors other than ANG may be critical to tRH biogenesis in different cell types or in 
response to different types of cellular stress. Much more remains to be uncovered about the 
specific mechanisms that lead to tRH accumulation. 
Chronic infections with HBV and HCV typically lead to more severe liver disease in 
human patients than in the chimpanzee model37,38. Disease severity may account for the 
differences we observed in tRH abundance between liver tissue from human subjects with 
chronic HCV infection and the chimpanzee samples. Interestingly, however, humans and 
chimpanzees exhibited similar increases in tRH abundance in chronic hepatitis B, suggesting 
that there may be a primary HBV-specific mechanism that directly regulates tRH biogenesis. 
Our study has some technical limitations. tRNAs are subject to many different chemical 
modifications39, several of which could impede library preparation and sequencing. This may 
have biased which tRNA-derived RNAs we detected. Also, we do not know how tRH abundance 
varies among the diverse cell types that populate the liver. Given that these small RNAs have 
not previously been studied in human tissue, we also have little appreciation of what functions 
these small non-coding RNAs have within the liver. Nonetheless, our finding that the 
intrahepatic abundance of tRHs is substantially increased in chronic viral infections of the liver 
and altered in HCC suggest that tRHs may have important, yet to be determined roles in liver 
disease. Thus, this study may have implications for disease pathogenesis and novel therapeutic 
strategies.  
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3.5 Materials and Methods 
 
The methods were carried out in accordance with the approved guidelines. 
Human subjects. Written informed consent was obtained from all human subjects. 
Ethics approval was obtained from the Ethics Committee for Human Genome/Gene Analysis 
Research at Kanazawa University Graduate School of Medical Science. 
Chimpanzee liver tissue. The chimpanzee samples used in this study were archived 
from previous studies and were collected prior to December 15, 2011. Chimpanzees were 
housed and cared for at the Southwest National Primate Research Center (SNPRC) of the 
Texas Biomedical Research Institute. The animals were cared for in accordance with the Guide 
for the Care and Use of Laboratory Animals, and all protocols were approved by the Institutional 
Animal Care and Use Committee. SNPRC is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) International. SNPRC operates in 
accordance with the NIH and U.S. Department of Agriculture guidelines and the Animal Welfare 
Act. Animals were sedated for all procedures. Animals are group-housed with indoor and 
outdoor access and an environmental enrichment program is provided by a staff of behavioral 
scientists.  
Small RNA-sequencing. RNA was isolated as described previously14. RNA purity was 
assessed with Nanodrop 2000 (Thermo Scientific) and integrity was determined with an Agilent 
2100 Bioanalyzer (Agilent). RNA integrity and sequencing quality were comparable for all 
specimens (Supplemental Table 2-4). Small RNA libraries were generated using Illumina 
TruSeq Small RNA Sample Preparation Kit (Illumina, San Diego, CA). Sequencing was 
performed on Illumina HiSeq 2000 platform. Bioinformatic analysis: Sequencing reads were 
trimmed using Cutadapt (parameters O -10 e 0.1) and were further analyzed in two different 
ways: (i) Mapped trimmed reads allowing no mismatches to all tRNA sequences (except 
pseudo-tRNAs and undefined tRNAs) downloaded from GtRNAdb16  (Figure 1b,c; Figure 2c,d; 
Supplemental Figure 1,2,4,7); (ii) Mapped trimmed reads to genomic regions spanning 
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annotated miRNA s40 (+/- 20 nts) and tRNA sequences (+/- 40 nts) using Bowtie 0.12.741 
allowing for no mismatches. Next, reads that did not map without mismatches were aligned to 
the same regions using SHRiMP2.2.242. SHRiMP2.2.2 seeds were set based on the length of 
the read allowing 1 mismatch anywhere in the body and up to 3 mismatches at the 3' end of the 
read (based on the length of the read). (Figure 1a right, Figure 2b, Supplemental Figure 7, 
Supplemental Table 4). Small RNA-sequencing data was deposited on GEO (GSE57381). 
AGO2-RNA Co-immunoprecipitation. FT3-7 cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies) and supplemented with 10% fetal calf serum and 2 
mM GlutaMAX (Life Technologies, Carlsbad, CA). Cells were cultured in a humidified incubator 
at 37oC and 5% CO2. Three technical replicates of 1x107 FT3-7 cells were harvested in lysis 
buffer [150 mM KCl, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, 1% Triton X-100, 5 mM DTT, 
Complete protease inhibitor mixture (Roche), and 100 U/mL RNaseOUT (Life Technologies)]. 
Lysates were centrifuged for 30 min at 17,000 × g at 4 °C and filtered through a 0.22-um filter. 
Filtrates were incubated with anti-human AGO2 mAb (RN003M, MBL International, Woborn, 
MA) or isotype control IgG (Abcam, Cambridge, England) at 4 °C for 2 h, followed by addition of 
30 µL of Protein G Sepharose (GE Healthcare) for 1 h. The Sepaharose beads were washed 
three times in lysis buffer and RNA extracted using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany). 
Small RNA real time quantitative PCR (RT-qPCR). Complementary DNA (cDNA) was 
synthesized using TaqMan MicroRNA Reverse Transcription Kit (Life Technologies) according 
to the manufacturer’s instructions. Real time PCR amplification was performed using TaqMan 
Universal Master Mix (Life Technologies) on the Bio-Rad CFX96 real time PCR detection 
system. U6, miR-24, let-7a, let-7f, RNU48, and RNU66 were all evaluated as potential 
housekeeping small RNAs for purposes of normalization. RNU48 was selected because it was 
the most consistent across disease groups. RT-qPCR reactions for human samples were 
performed in triplicate. RT-qPCR reactions for chimpanzee samples were performed in 
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duplicate. The following TaqMan assays were purchased from Life Technologies: miR-122 
(product number 4427975; 002245) and RNU48 or SNORD48 (product number 4427975; 
001006). Primers for the custom TaqMan assays (5’ tRH-Gly and 5’ tRH-Val) were designed using 
5’-GCAUUGGUGGUUCAGUGGUAGAAUUCUCGCCU-3’ for 5’ tRH-Gly and 5’-
GUUUCCGUAGUGUAGUGGUUAUCACGUUCGCCU-3’ for 5’ tRHVal.  
Metabolic Radiolabeling and Measurement of Nascent Protein Synthesis. Huh7 
cells were seeded onto the wells of 6-well cell culture plates at a density of 2x105 cells/well and 
incubated overnight to allow cell attachment. Cells were transfected with 50 nM and 100 nM of 
5’ tRHGly (5’-GCAUUGGUGGUUCAGUGGUAGAAUUCUCGCCU-3’), 5’ tRHVal (5’-
GUUUCCGUAGUGUAGUGGUUAUCACGUUCGCCU-3’), or scramble (5’-
GCAUUCACUUGGAUAGUAAAUCCAAGCUGAA-3’)21 (all from Integrated DNA Technologies, 
Coralville, IA) oligonucleotide after replacing cell culture medium with methionine- and cysteine-
deficient DMEM (Life Technologies) and cultured for further 12 hrs. Cells were then 
metabolically radiolabeled for 12 hrs with 200 µCi/well of Express Protein Labeling Mix 
containing [35S]methionine and [35S]cysteine (PerkinElmer, Waltham, MA) in the presence or 
absence of 50 µg/ml puromycin and lysed with lysis buffer (20 mM Tris-HCl [pH 7.4] containing 
150 mM NaCl, 1% Triton X-100, 0.05% SDS, and 10% glycerol) supplemented with 50 mM 
NaF, 5 mM Na3VO4, and a protease inhibitor cocktail (Complete; Roche, Mannheim, Germany). 
The protein concentration of cell lysates was determined by the Bio-Rad Protein Assay (Bio-
Rad), and 10 µg (total protein) of cell lysates was subjected to SDS-PAGE followed by staining 
gels with the Sypro Ruby Protein Gel Stain (Bio-Rad, Hercules, CA) and autoradiography. 
Immunohistochemistry (IHC). Staining was performed by immunoperoxidase 
technique with an Envision kit (DAKO Japan). Primary antibodies used were against b-actin 
(Cell signaling technology, #4967, Beverly, MA) and Human Angiogenin Affinity Purified 
Polyclonal Ab (R and D Systems, AF265, Minneapolis, MN). 
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Figure 3.1 tRH abundance in HBV- and HCV-infected liver. (a) (left) Read length distribution 
of 14-40 nt RNAs in non-malignant liver from uninfected, HBV-, or HCV-infected subjects (n=4 
each), and FT3-7 cells (n=3 replicates). (right) Proportion of reads mapping to miRNA versus 
tRNA loci. Boxes represent median ± 1.5 * interquartile range. (b) tRNA coverage plot from the 
average of the 20 non-cancer samples. Dot size represents percent of reads mapping at each 
base position within each tRNA (top 20 by average abundance). The anticodon is red, with 5’ 
bases green and 3’ bases blue. Gray: bases of RNAs that are non-tRHs. See Supplemental 
Figure 1. (c) Proportion of mapped reads aligning to miR-122 versus the five most abundant 
tRNA-derived RNAs. (d) (left) Expression levels (RT-qPCR) of miR-122, 5’ tRHGly 
(“Gly[C/G]CC”) and 5’ tRHVal (“Val[A/C]AC”) in uninfected (n=5-6), HBV-infected (n=6-9) and 
HCV-infected (n=14) human liver. Numbers of samples differ due to limited RNA. (right) Similar 
results from uninfected (n=5), HBV-infected (n=9), and HCV-infected C (n=5) chimpanzees. 
RNU48 was used as a normalizer. *P < 0.05; **P < 0.01; ***P < 0.005 by Mann-Whitney U-test. 
(e) ClustalW43 multiple sequence alignment of representative tRNAGly and tRNAVal genes from 
which 5’ tRHGly and 5’ tRHVal could originate (see Supplemental Figure 3). tRNAs regions are 
highlighted according to the color scheme in panel (b). The box identifies a unique conserved 
sequence motif described in the text. “Mapped reads” represents all reads aligning to miRNAs 
or tRNAs (see Methods). 
 
	  	   46 
 
 
Figure 3.2 5’ tRH abundance in HBV- and HCV-associated hepatocellular carcinoma. (b) 
Abundance (RT-qPCR) of (left) 5’ tRHGly (Gly[C/G]CC) and (right) 5’ tRHVal (Val[A/C]AC) in (top) 
non-malignant (n=9) and cancer tissue (n=10) from HBV-infected subjects, and (bottom) non-
malignant (n=14), and cancer tissue (n=15) from HCV-infected subjects. Box and whisker plots 
are overlaid with data from each sample; whiskers extend to 1.5 * interquartile range. P-values 
calculated using Mann-Whitney U-test. *P < 0.05; **P < 0.01; ***P < 0.005. (b) Proportion of 
mapped reads aligning to tRNAs for the paired cancer and non-cancer tissue from subjects with 
chronic hepatitis B (n=3) and hepatitis C (n=4) (c) Correlation heatmap of tRNA-derived RNA 
expression profiles determined by small RNA sequencing. The colors of the cells represent 
Spearman’s rank correlation coefficients of the relative levels of the 10 most abundant tRNA-
derived RNAs between all pairs of tissue samples sequenced (n=20). (d) Proportion of mapped 
reads that align to 5’ tRHGly and 5’ tRHVal in non-malignant and cancer tissue from (top) HBV-
infected and (bottom) HCV-infected subjects. “Mapped reads” represents all reads aligning to 
miRNAs or tRNAs (see Methods). 
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Figure 3.3 Angiogenin expression in viral hepatitis and hepatocellular carcinoma. (a) 
Normalized ANG mRNA levels from previously generated liver microarray data 14 from 
uninfected subjects (n=6), non-malignant (n=7) and liver cancer (n=8) tissue from HBV-infected 
subjects, and non-malignant (n=11) and cancer tissue (n=15) from HCV-infected subjects. **P < 
0.01; ***P < 0.005, calculated by Mann-Whitney U-test. (b) Scatter plot of the levels of 5’ tRHs 
(RT-qPCR, -dCT normalized to RNU48) and ANG mRNA (microarray). 5’ tRHGly (“Gly[C/G]CC”): 
uninfected subjects (n=7), non-cancer (n=7) and cancer (n=8) liver tissue from chronic hepatitis 
B subjects, and non-cancer (n=11) and cancer (n=15) liver tissue from chronic hepatitis C 
subjects; 5’ tRHVal: uninfected subjects (n=6), non-cancer (n=7) and cancer (n=8) liver tissue 
from chronic hepatitis B subjects, and non-cancer (n=11) and cancer (n=15) liver tissue of 
chronic hepatitis C subjects. (c) Scatter plot of the levels of 5’ tRHs (RT-qPCR, -dCT normalized 
to RNU48) and ANG protein expression (normalized to β-actin) determined by immunoblot 
analysis. (d) Immunohistochemistry staining for ANG in formalin-fixed non-tumor (NT) and 
tumor tissue (T) from HBV-infected subject #10. (Right) Magnified view of non-tumor (NT). (e) 
ANG staining in adjacent tumor nodules (T1 and T2) and in non-tumor (NT) tissue from HCV-
infected subject #7. 
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Supplemental Figure 3.1 Example of a tRNA coverage plot for small RNAs detected in non-
malignant tissue from HBV-infected subject 6. Each line in the coverage plot represents tRNA 
families from which the tRNA-derived RNA could originate. The tRNAs are listed using a 
nomenclature that groups tRNA gene paralogs by sequence: “X-Y-Z”, where X is the tRNA 
amino acid and anticodon, Y is the number of tRNA genes with the identical sequence, and Z is 
a unique identifier for each tRNA family. For example, GlyGCC-6-1 is a tRNA that carries Gly 
with a GCC in the anticodon, and which could be derived from 6 different tRNA genes and its 
unique ID is 1. Supplemental Table 5 provides the new tRNA sequence ID, the position of the 
anticodon for each tRNA sequence, the tRNA sequence, and all the tRNA genes to which each 
sequence ID corresponds. If a tRNA-derived RNA could have originated from multiple 
sequences, each is listed separately in the label for each row. If multiple sequences have the 
same anticodon, then the number identifiers are each listed, comma separated after the amino 
acid and anticodon. Superimposed on the coverage plot are boxes (peach) that show the name 
of a tRNA-derived RNA type and arrows pointing to examples of each type. Different tRNA-
derived RNAs are named as suggested by Garcia-Silva et al.15, differentiating between tRNA-
fragments (tRFs) and tRNA-halves (tRHs). Also shown are novel tRNA-derived RNAs that we 
have termed “second quarter” (2Q) or “third quarter” (3Q) tRNA fragments, depending on where 
they originate from within the tRNA. 
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Supplemental Figure 3.2 (a) Proportional abundance of the top five tRNA-derived RNAs. 
Proportion of all tRNA-derived RNAs represented by each of the five most abundant tRNA-
derived RNAs (rank based from Fig. 1c) in uninfected and non-malignant chronic viral hepatitis 
liver tissue. (b) Correlation between the log10 (relative abundance) of the 60 most abundant 
tRNA-derived RNAs (averaged across all 12 samples) and (top) codon usage (from the 
Genomic tRNA Database) and (bottom) tRNA gene number. Symbols are shaded according to 
the percent codon usage, or number of full-length tRNAs that each tRNA-derived RNA could 
originate from. 
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Supplemental Figure 3.3 Multiple sequence alignment of tRNA genes from which 5’ tRHs 
could have originated.  (a) Nucleotide sequences of tRNA genes from which 5’ tRHGly 
(“Gly[C/G]CC”) could originate. (b) Nucleotide sequences of tRNA genes from which 5’ tRHVal 
(“Val[A/C]AC”) could originate. (c) Nucleotide sequences of tRNA genes from (a) and (b). (d) 
Nucleotide sequences from representative tRNA genes from which the 10 most abundant tRNA-
derived RNAs in non-malignant tissue could originate. Multiple sequence alignments were 
generated by ClustalW276 of tRNA sequences77. tRNA nomenclature is described in the legend 
to Supplemental Figure 1. The anticodon is highlighted in yellow. 
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Supplemental Figure 3.4 tRNA gene number and codon usage. The height of each bar depicts 
the number of tRNA genes from which each of tRNA-derived RNAs could be derived, while the 
color represents the percent codon usage for that tRNA (downloaded from Genomic tRNA 
database). Representative tRNA names for tRNA-derived RNAs are ordered from left to right 
based on the average tRNA-derived RNA abundance in non-malignant tissues. 
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Supplemental Figure 3.5  ANG RNA-seq estimated count (RSEM) from The Cancer Genome 
Atlas (TCGA) RNA-sequence data: non-cancer (n=6) and cancer (n=12) liver tissue from 
chronic hepatitis B subjects, and non-cancer (n=5) and cancer (n=18) from chronic hepatitis C 
subjects. ***P < 0.005, calculated by Mann-Whitney U-test. 
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Supplemental Figure 3.6  Immunoblots showing angiogenin (ANG) expression in uninfected 
tissues and in paired non-malignant and cancer tissue samples. (a) ANG protein expression 
determined from immunoblots (see panels b-d). (b, c, d) ANG blot intensity measured by 
densitometry was normalized to b-actin signal (loading control) in blots of proteins extracted 
from uninfected (n=10) and paired non-malignant (top rows) and cancer (bottom rows) tissues 
from HBV- (n=10) and HCV-infected (n=16) subjects. Densitometry quantitation (ANG/b-actin) is 
shown above the blots. In panels (c) and (d), lightly shaded bars represent non-malignant 
tissue, and darkly shaded bars cancer tissue.  
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Supplemental Figure 3.7 To determine whether tRHs associate with argonaute 2 (AGO2), the 
main effector protein within RISC, we sequenced small RNAs associating with AGO2 in a pull-
down assay and compared these to the total small RNA pool in FT3-7 hepatoma cells. (a) 
AGO2 immunoprecipitation. Immunoblots of products from immunoprecipitation experiments (n= 
3 technical replicates) carried out with antibody against AGO2 and isotype-matched control 
(IgG). (b) Length distribution of reads from sequencing of small RNAs associating with AGO2 
pull-down (n=3 replicates), isotype control (IgG) pull-down (n=3 replicates), and total RNA from 
FT3-7 cells. The first peak (17 nts) in total RNA is from ribosomal RNA. (c) Median proportion of 
reads mapping to miRNA versus tRNA loci in FT3-7 cells and AGO2 immunoprecipitates shown 
in comparison with small RNA from liver of uninfected subjects and malignant and non-
malignant tissue from subjects with chronic hepatitis B and C (n=4 each). (d) Median proportion 
of reads mapping to tRNAs that correspond to tRFs (<23 nts), tRHs (>28 nts), or neither 
(“other”). 
Approximately 14% of small RNAs in FT3-7 cells mapped to tRNA genes, compared to 
<1% of those in the AGO2-associated fraction. Furthermore, the relative abundance of 5’ tRHs 
was ~3-fold less in AGO2-associated RNA compared to the total small RNA pool. Thus, tRHs 
are not selectively associated with AGO2 and likely do not function generally as miRNAs. 
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Supplemental Figure 3.8 Metabolic labeling of newly synthesized proteins in human hepatoma 
(Huh7) cells transiently transfected with synthetic 5’ tRHGly (Gly[C/G]CC), 5’ tRHVal 
(Val[A/C]AC) (the two most abundant tRHs found in human liver), or a 31 nt scrambled 
sequence oligonucleotide (50 nM or 100 nM each). (a) The top panel shows [35S]-labeled 
proteins synthesized in the 12 hours prior to cell lysis separated by SDS-PAGE (phosphoimager 
analysis); the bottom panel shows total protein abundance in each cell lysate (Sypro-Ruby 
staining). The lane labeled “PUR” was loaded with lysate from cells treated with puromycin. (b) 
Human hepatoma (RCF-26) cells were transfected with fluorescently labeled 5’ tRHVal (20 nM) 
to gage transfection efficiency. Signal appears present in the majority of cells. (c) Densitometry 
traces from SDS-PAGE loaded with [35S]-labeled protein products (100 nM results in panel a). 
Transfection of cells with high concentrations of tRHs appears to have no significant effects on 
cellular translation. 
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Chapter 4 
 
tDRmapper: challenges and solutions to mapping, naming, and quantifying tRNA-derived 
RNAs from human small RNA-sequencing data 
4.1 Overview 
 
Small RNA-sequencing has revealed the diversity and high abundance of small RNAs 
derived from tRNAs, referred to as tRNA-derived RNAs. However, at present, there is no 
standardized nomenclature and there are no methods for accurate annotation and quantification 
of these small RNAs. tRNA-derived RNAs have unique features that limit the utility of 
conventional alignment tools and quantification methods. We describe here the challenges of 
mapping, naming, and quantifying tRNA-derived RNAs and present a novel method that 
addresses them, called tDRmapper. We then use tDRmapper to perform a comparative analysis 
of tRNA-derived RNA profiles across different human tissues and diseases. 
 
4.2 Introduction 
 
Transfer RNAs (tRNAs) are non-coding RNAs that deliver amino acids to ribosomes 
during translation. tRNA-derived RNAs (tDRs) are small RNAs that are enzymatically processed 
from either nascent pre-tRNA transcripts or mature tRNAs12. Their regulated biogenesis and 
well-defined 5’ and 3’ ends indicate that they are not products of tRNA degradation16. tDRs are 
generated in organisms from all domains of life15. They are derived from most tRNA genes and 
produced in varying abundance, in a variety of different sizes, and from different regions of the 
tRNA. Several functions have been attributed to tDRs such as post-transcriptional17,78 and 
translational repression18, stress granule formation19, and protection from apoptosis20; however, 
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all of these have been in the context of cell culture. The role of tDRs in human health is only 
now starting to emerge. tDRs may play a role in neurodegeneration25, cancer78,79, as well as 
immune modulation22, and we previously showed that tDRs are significantly increased in the 
liver tissue of patients with chronic viral hepatitis and decreased in liver cancer16.  
Despite the potential biomedical significance of tDRs, the field is lagging behind other 
small RNA fields in terms of genomic annotation and strategies for quantification from small 
RNA-sequencing (small RNA-seq) data. This is due in large part to: (a) the unique 
computational challenges of mapping tDRs from small RNA-seq data and (b) the lack of a 
standardized nomenclature for tDRs. 
a) While small RNA-seq has enabled the discovery of tDRs, these small RNAs are difficult 
to map accurately for at least three reasons: 
(1) Exact copies of tRNA genes are present in numerous locations throughout the 
human genome, and annotation of tRNAs in the human genome is still 
incomplete. This means that small RNA-seq reads corresponding to tRNA-
derived RNAs can map with equal fidelity to numerous locations throughout the 
genome (multi-mapping), which leads to ambiguity about the precise origin of the 
tRNA-derived RNA. 
(2) tDRs are derived from both the nascent pre-tRNAs and the processed, mature 
tRNAs. The maturation process of eukaryotic tRNAs includes several steps, such 
as the removal of 5’ leader sequence and 3’ trailer sequence, the addition of a 
non-templated “CCA” to the 3’ end, and the excision of introns. These changes 
during maturation need to be accounted for when mapping tRNA-derived RNA 
reads. For example, spliced reads (those derived from the sequence flanking the 
spliced intron) or reads that contain a non-templated 3’-end “CCA” will not map to 
the genome. 
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(3) tRNAs are subject to extensive chemical modifications at specific nucleotide 
positions during maturation80. As a result, tDRs most likely harbor these 
modifications, which can lead to errors during cDNA synthesis due to reverse 
transcriptase pausing and mis-incorporation of nucleosides81. These errors 
manifest in small RNA-seq reads as mismatches and deletions relative to the 
reference tRNA sequence. These mismatches/deletions will be referred to as 
“error type.” 
b) There is no standardized nomenclature for tDRs. tDRs are produced in a variety of 
different sizes, from a variety of different tRNAs, and from a variety of different locations 
within the tRNAs, all of which present challenges for a coherent naming system. A 
standard naming scheme is critical to facilitate future research. For example, it is at 
present extremely difficult to use published studies to define the bio-distribution of 
specific tDRs (the tissues and conditions in which specific tDRs are expressed) because 
the same or similar tDR is often referred to by completely different names (and in some 
cases a name is not given at all). 
In this study we introduce a tool designed to address the challenges of mapping, 
naming, and quantifying tDRs, called tDRmapper. tDRmapper was designed specifically for 
human small RNA-seq data (single-end, 50x) generated on the Illumina sequencing platform 
using cDNA libraries that were prepared using the Illumina TruSeq protocol. We used 
tDRmapper to analyze publically available small RNA-seq datasets (total n=45) from four 
categories of cell types/tissues. These analyses helped shape the final version of the tool and 
also led to the discovery of new types of tDR species as well as novel insights about potentially 
varying patterns of tRNA modifications in different human tissues and diseases. 
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4.3 Results and Discussion 
 
To the best of our knowledge, no tDR specific aligner has been made publically 
available. tDRmapper aligns small RNA-seq reads to tRNA sequences, allowing for and 
quantifying mismatches and deletions. tDRmapper was written with its own alignment scheme 
and does not use a previously developed aligner, such as Bowtie 282. While Bowtie 2 does allow 
for mismatches and deletions, it is a more general mapping tool, whereas tDRmapper is 
specifically designed for mapping reads to tRNAs, which have several unique features that are 
described below. Also, while methods for assessing RNA modifications from small RNA-seq 
data have been previously developed, such as HAMR81, they do not quantify tDR species. 
tDRmapper defines and quantifies specific tDRs and automatically generates visualization of 
both pre- and mature tDR profiles.  
 
4.3a Small RNA-seq datasets from four categories of human cell types / tissues 
 
We analyzed a diverse array of human small RNA-seq datasets to guide tool 
development and to ensure that tDRmapper is not biased to one specific tissue or disease. We 
also used some of the results from these analyses as examples to illustrate the importance of 
each step in tDRmapper. 
Previously, we reported that tDRs are highly abundant in liver tissue and both the total 
tDR abundance and the relative expression of individual tDRs were associated with chronic 
hepatitis B, chronic hepatitis C, and hepatocellular carcinoma16. In this study, the analysis of the 
different categories of cell types/tissues revealed that the high abundance of tDRs is not specific 
to liver disease, but rather tDRs are present in high abundance in other human tissues and 
fluids as well (Figure 4.1). The four categories of cell types/tissues are described below: 
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Primary liver tissue – Chronic viral hepatitis and liver cancer16: 
Hepatitis B and hepatitis C viruses both infect the liver, leading to chronic liver infection and 
cancer. Both viruses together are responsible for ~80% of the world’s liver cancer cases. Liver 
tissue was collected during surgical resection in Kanazawa, Japan and small RNA-seq was 
performed on the RNA isolated from matched malignant and non-malignant tissue from patients 
with advanced chronic hepatitis B (n=4) or chronic hepatitis C (n=4), as well as from liver tissue 
from uninfected individuals (n=4) undergoing liver surgery due to metastatic colon cancer 
(GSE57381).  
 
Primary colon tissue – Crohn’s disease83: 
Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract. These datasets 
were generated from a study that performed small RNA-seq on primary colon tissue from 
subjects with Crohn’s disease, including both the uninflamed (n=21) and inflamed (n=6) 
components, as well as colon tissue from individuals without Crohn’s disease (n=13). The small 
RNA-seq was performed in the same sequencing facility as the liver samples described above 
(GSE66209). 
 
Seminal fluid – Prostate cancer84: 
The non-sperm fractions of seminal fluid can be used to screen for biomarkers of prostate 
cancer. These datasets were generated from a study that performed small RNA-seq on a 
pooled sample of seminal fluid RNA from men with prostate cancer (n=6) and a pooled sample 
of seminal fluid RNA from men without prostate cancer (n=6) (GSE56686). 
 
Stem and progenitor cells – Phases of embryonic development: 
The University of California at San Diego, through the NIH Roadmap Epigenomics Project, 
generated small RNA-seq data for ten samples (GSE16256): H1 cells (human embryonic stem 
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cells) with no treatment (n=2), H1 cells treated with BMP4 for differentiation to trophoblasts 
(n=2) and mesendoderm (n=2), H1-derived neuronal progenitor cells (n=2), and H1-derived 
mesenchymal stem cells (n=2). 
 
4.3b Details of tDRmapper 
 
We developed the first publically available tool, called tDRmapper, for mapping, naming, 
and quantification of tDRs (Figure 4.2). Each step of tDRmapper is described below: 
 
Step 1: Sequencing reads are filtered for quality 
tDRmapper takes as input adapter-trimmed small RNA sequencing reads in FASTQ 
format. The program then discards the following types of reads: 
(1) If the Phred +33 quality score drops below 28 at any individual position along the 
length of the read. This filter is implemented in order to increase the likelihood that 
mismatches/deletions in the reads with respect to the reference sequence are biological 
and not due to errors of the sequencing machine. The score threshold is very 
conservative, so the mismatch/deletion (“error type”) calls are high confidence. 
(2) If the read is smaller than 14 nucleotides or larger than 41. The lower bound (14 nts) 
is especially critical for mitigating mapping ambiguity (the smaller the read the more 
locations it can map to just by chance, especially when allowing for mismatches and 
deletions). 
(3) If the read does not occur in the FASTQ file at least 100 times. This filtration step 
limits the noise from the lowly expressed small RNAs. The threshold of 100 can be 
easily transformed into a percentage of total reads rather than a number of reads. 
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Step 2: Filtered reads are aligned to mature and pre-tRNAs following an “error type” hierarchy.  
 
Alignment to tRNA sequences 
Reads are aligned to mature and pre-tRNA sequences and not the genome for four 
reasons: 
(1) The total number of human tRNA genes is not known and tRNA annotation across 
the human genome remains an open area of research. Therefore, some reads that map to 
annotated tRNAs will also map equally well to other regions of the genome that may also be 
tRNAs, but are currently unannotated. Mapping the small RNA-seq reads to known tRNA 
sequences avoids this ambiguity. Of the 615 currently annotated human tRNA genes in The 
Genomic tRNA Database85 (gtRNAdb), 239 have one or more annotated identical copies across 
the genome. For example, one of the tRNA-Histidine genes has 9 exact copies across the 
human genome and one of the tRNA-Aspartate genes has 11. Mapping reads that are derived 
from multi-copy tRNA genes to the whole genome would complicate tDR quantification. Our 
solution is to aggregate the human tRNA genes that have identical sequences (both pre- and 
mature sequences) into “families” and give those “families” one name (FASTA included with 
tDRmapper). 
(2) Many tDRs are thought the be derived from processed, mature tRNAs. As stated 
previously, tRNAs undergo specific changes during maturation and as a result, the sequences 
of mature tRNAs do not reflect the genomic template from which they are produced. These 
changes during maturation need to be accounted for when mapping tRNA-derived RNA reads. 
(3) Aligning to annotated tRNA sequences instead of the genome has the added benefit 
of a much smaller search space, which means that mismatches and deletions can be accounted 
for in a much more computationally tractable manner. 
tRNA sequences were downloaded from gtRNAdb. To generate the mature tRNA 
libraries, we removed the predicted intronic sequences (if present) and added an additional 3’ 
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terminal “CCA” to each tRNA. To generate the pre-tRNA libraries, we included 40 nucleotides of 
flanking genomic sequence on either side of the original tRNA sequence. 
 
Error type 
Small RNA-seq reads are aligned with an “error type” hierarchy (Figure 4.2) and each 
“error type” is annotated and quantified. The reads are first mapped to mature tRNA sequences 
allowing for exact matches only. The reads that do not align are then funneled to the next step, 
where the reads are mapped to pre-tRNA sequences allowing for exact matches only. The 
reads that do not align exactly to either the mature tRNA or the pre-tRNA are then mapped to 
mature tRNA sequences, allowing first for one mismatch, then one deletion, two mismatches, 
two deletions, and lastly a three base pair deletion. tDRmapper is written in a modular fashion, 
meaning each “error type” alignment is written in a separate script, enabling the user to easily 
switch the sequential order in which the algorithm searches for different “error types.” This may 
be useful if, for example, there emerges a compelling biological reason to prioritize one deletion 
over one mismatch or to speed up the program by not allowing two mismatches. 
We allow for and annotate “error types” in reads mapping to mature tRNA sequences 
because mature eukaryotic tRNAs have on average 17 chemical modifications80. Some of these 
modifications can lead to pausing and mis-incorporation of nucleosides, which manifest as 
mismatches and deletions in the small RNA-seq reads81,86. We only allow for mismatches and 
deletions when mapping to mature tRNAs, and not pre-tRNAs, because we assume that only 
mature tRNAs are subject to extensive chemical modifications. If future research overturns this 
assumption, then the algorithm can be amended accordingly in a relatively straight-forward 
manner. (We note here that some modifications could also lead to reverse transcriptase aborts, 
which would result in an under-representation of certain types of reads in small RNA-seq data. 
While this is an important issue, it is best addressed by experimental solutions, so we do not 
discuss this in tDRmapper). 
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tRNA modifications have been associated with disease87. We sought to annotate the 
locations and “error types” across different tissues and diseases, as these “error types” may 
represent sites of chemical modification. Figure 4.3A shows the “error type” proportion across all 
tRNAs for all of the datasets analyzed. Overall, most reads align to tRNAs exactly; however, 
there are some tRNAs that have a higher abundance of mismatches and deletions than others, 
and also exhibit substantive variation in “error types” across tissues (Figure 4.3B). For example, 
in the liver and seminal fluid samples, ~20% of the reads that mapped to tRNA-Glu-CTC-1-7 
only aligned after allowing for a three base pair deletion, while in colon tissue and H1 cells, this 
accounted only for ~4% and <0.5%, respectively (Figure 4.3B). This example demonstrates 
tissue-specific profiles of “error types” and the importance of allowing for deletions and 
mismatches in tDR alignment, since without this feature, ~50% of reads aligning to tRNA-Glu-
CTC-7-1 in the liver tissue and seminal fluid samples would be discarded. 
We also found that “error type” profiles can vary by disease within the same tissue for 
specific tDRs (Figure 4.3C, D). For example, on average, 8% of reads that correspond to tRNA-
Pro-CGG-1-3 in the inflamed Crohn’s tissue only mapped after allowing for a three base pair 
deletion, whereas in 5/6 of the matched uninflamed tissue, no reads mapped after allowing for a 
three base pair deletion (Figure 4.3C). Also, reads that mapped to tRNA-Gly-GCC-1-5 had a 
significantly (P = 0.001) higher incidence of one mismatch in the non-cancer liver samples 
compared to the matched cancer samples (Figure 4.3D). 
 
Step 3: Aligned reads are named based on read size and location of derivation from mature or 
pre-tRNAs 
 
One of the primary challenges in the tDR field is that there is no standardized naming 
system. We propose a nomenclature that is both concise and informative (Figure 4.4). 
tDRmapper will assign to each tDR a name that has three components: 
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1) The first component of the tDR name indicates the parent tRNA “family” from which 
the tDR is derived. 
a. For the mature tRNA sequences, the “family” names consist of four parts, “W-
X-Y-Z”, where W is the tRNA amino acid (sometimes preceded by “nmt-
tRNA,” which means “nuclear encoded mitochondrial tRNA”), X is the anti-
codon, Y is a unique identifier for each tRNA family, and Z is the number of 
mature tRNA genes with the identical sequence. For example, Asp-GTC-2-11 
represents a mature tRNA “family” sequence that could be derived from 11 
different tRNA genes, has a unique ID, “2”, bears the GTC anti-codon, and 
associates with Aspartate. This naming scheme builds on the nomenclature 
for tRNAs used by gtRNAdb. 
b. For the pre-tRNA sequences, the “family” names consist of 6 parts, “pre-W-X-
Y-Z.n”. This reflects the same naming scheme described above in (a), but 
with the prefix “pre” and the suffix “.n”. The “.n” refers to the number of pre-
tRNAs from the W-X-Y mature tRNA family that have the identical pre-tRNA 
sequence. From among those with the identical pre-tRNA sequence, the 
largest “Z” is chosen for the “family” name. For example, the pre-Gly-TCC-2-
5.4 sequence accounts for four pre-tRNAs with identical sequence. The 
family members included under this name are pre-Gly-TCC-2-2, pre-Gly-
TCC-2-3, pre-Gly-TCC-2-4, and pre-Gly-TCC-2-5. 
 
2) The second component of the tDR name indicates the size of the tDR. tDRmapper 
determines the primary tDR associated with a parent tRNA by counting the number 
of positions in the tRNA that have >50% coverage (where coverage at a position is 
defined as the percent of all reads mapping to the tRNA at that position). If the 
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primary tDR sequence is <41 nts and =>28 nts, it is defined as a tRNA-half (tRH), 
and if it is >14 nts and <28 nts, it is defined as a tRNA-fragment (tRF).  
 
3) The last component of the tDR name indicates the region in the mature or pre-tRNA 
from which the read is derived. 
 
a. For the tDRs derived from mature tRNAs (Figure 4.4A), we use a generalized 
tRNA secondary structure (Methods). First we determine if a read is derived 
from the 5’ or 3’ end of the tRNA. If not, then we assess whether it overlaps 
the D-loop, anti-codon loop, or T-loop by at least one nucleotide. Details are 
provided below:  
i. “5’” is added as a suffix to the tDR name if the coverage is >50% at 
position +1 of the tRNA (first nucleotide at the 5’-end). 
ii. “3’” is added as a suffix to the tDR name if the coverage is >50% at 
position -7 of the tRNA (7 nucleotides from the 3’ end). Position -7 was 
used instead of position -1 due to the tapering signal (graded reduction in 
coverage) observed at the 3’ ends of some tDRs. 
iii. “D”, denoting the D-loop, is added as a suffix to the tDR name if the 
coverage is >50% at any position between 13 and 22, and is not >50% at 
position 1. 
iv. “A”, denoting the anti-codon loop, is added as a suffix to the tDR name if 
the coverage is >50% at any position between 31 and 39, and not >50% 
at position 1 or position -7. 
v. “T”, denoting the T-loop, is added as a suffix to the tDR name if the 
coverage is >50% at any position between -23 and -15, and not >50% at 
position -7. The T-loop is denoted using positions determined from the 3’ 
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end (as opposed to the D-loop and anti-codon loop which are denoted 
using positions determined from the 5’-end – see [iii] and [iv] above) due 
to variability in the size of the region between the anti-codon loop and the 
T-loop (which contains what is known as the “variable loop”). 
  
b. For the tDRs derived from pre-tRNAs, we annotate where in relation to the 
header, trailer, and tRNA “body” the tDR is derived (where “body” is defined as 
the full-length tRNA sequence provided by gtRNAdb). Details are provided below 
(Figure 4.4B): 
i. “0” is added as a suffix to the tDR name if the coverage is >50% at one or 
more nucleotides 5’ of the tRNA body, the leader sequence. 
ii. “1” is added as a suffix to the tDR name if the coverage is >50% at one or 
more nucleotides 3’ of the tRNA body, the trailer sequence. This 
annotation is consistent with the already described “tRF-1 series”88, which 
are tRFs derived exclusively from trailer sequences.  
iii. “B”, denoting tRNA “body”, is added as a suffix to the tDR name (after 
either a “0” or a “1”) if the coverage is >50% at any position in the body of 
the tRNA. 
Finally, a primary tDR is only named in the manner described above if at least one 
position of the tDR has coverage >66%. Otherwise the name given is “undefined” (Figure 4.4A). 
This conservative threshold is intended to ensure that a primary tDR is identified only when it 
represents the vast majority of the reads mapping to the parent tRNA. 
  
Step 4: tDRs are quantified based on two features, the fraction of reads aligning to the parent 
tRNA and the maximum coverage across all positions of the tRNA 
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The tDRs are quantified using the following equation: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒   = #  𝑜𝑓  𝑟𝑒𝑎𝑑𝑠  𝑚𝑎𝑝𝑝𝑒𝑑  𝑡𝑜  𝑡ℎ𝑒  𝑡𝑅𝑁𝐴#  𝑜𝑓  𝑟𝑒𝑎𝑑𝑠  𝑚𝑎𝑝𝑝𝑒𝑑  𝑡𝑜  𝑎𝑙𝑙  𝑡𝑅𝑁𝐴𝑠 ×  ℎ𝑖𝑔ℎ𝑒𝑠𝑡  𝑝𝑟𝑜𝑝.    𝑜𝑓  𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒  𝑜𝑓  𝑡𝑅𝑁𝐴 ×100 
 
For example, the relative abundance of Val-CAC-1-6 is 4.6% in the neural progenitor 
cells (Figure 4.5D). In this sample, there are 45,347 reads mapping to Val-CAC-1-6; 679,288 
reads mapping to all the tRNAs; and the highest proportion of coverage across the tRNA-Val-
CAC-1-6 is 0.69, meaning the area with the highest read depth across tRNA-Val-CAC-1-6 
accounts for 69% of the reads. 
Also, every instance a read maps to a tRNA it is counted once. For example, in the 
control colon patient #30, the read “GTTTCCGTAGTGTAGTGGTTATCACGTTCGCCT” occurs 
1,415,079 times in the FASTQ file, maps to six different tRNA-Val “families,” and therefore is 
quantified as 1,415,079 for each of the families. 
 
 There are two reasons for this quantification method: 
 
(1) Small RNA-seq reads will often map with equal fidelity to several tRNA families. A 
common strategy for handling multi-mapping is fractional assignment of reads. Fractional 
assignment in its most simplistic form divides the read count by the number of locations to which 
the read aligns. One goal of fractional mapping is to capture all locations at which transcription 
could be occurring. But, in this scheme, tDRs that derive from tRNAs with many copies 
throughout the genome will be artificially under-quantified. Since the goal of tDRmapper is to 
quantify the total abundance of tDRs, not gain information about transcriptional regulation of 
tDRs, we do not use fractional mapping.  
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(2) This quantification method has high resolution since each primary tDR from each 
parent tRNA family is quantified separately. However, the output files do allow for user-driven 
post-hoc quantification. For example, the user can decide to quantify tDRs by aggregating tRNA 
families (defined here as those tRNAs with identical sequence) into even larger super families 
based on the isodecoder or the amino acid. This would not allow for per base resolution, but it 
would simplify the signal. 
 
Step 5: Quantified tDRs are visualized as color-coded coverage maps 
 
tDRmapper automatically generates a separate visualization of the pre-tRNA-derived 
tDR profile and mature tRNA-derived tDR profile for each sample. Figure 4.5 shows one 
example mature tRNA coverage map from each of the four categories of cell types/tissues. The 
y-axis of the tRNA coverage map shows the top 50 most highly abundant tDRs in descending 
order, and also includes the relative abundance (described in Step 4 above). The x-axis shows 
the position within the tRNA. Each row displays the percent read coverage at each position, the 
nucleotide sequence of each tRNA, and the positions and proportions of any “error types” that 
are present at >5% of the reads that map to a given position. This coverage map enables the 
user to easily visualize the global tDR profile of a sample.  
The coverage maps in Figure 4.5 show that tDR profiles can vary dramatically across 
tissues. For instance, the most abundant type of tDRs in the seminal fluid (Figure 4.5B) and liver 
(Figure 4.5C) are of the type tRH-5’, while the colon (Figure 4.5A) and neural progenitors 
(Figure 4.5D) have a greater abundance of tRF-3’s. It is worth noting that these differences are 
not attributable to differences in library preparation or sequencing technology, because the liver 
and colon libraries were prepared and sequenced using the same protocols in the same 
sequencing facility.  
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As discussed above, “error types” serve as a proxy for chemical modifications and 
therefore can vary across different tissues and diseases (Figure 4.3). Our coverage maps 
annotate the specific “error types” present, enabling comparisons at single nucleotide resolution. 
For example, for Glu-CTC-1-1, all of the examples shown have a one base deletion at positions 
7 or 8 accounting for ~20%-30% of the reads that span that position. However, the liver and 
seminal fluid samples also have a three base deletion at anywhere between positions 6 and 10 
(though at positions 7 and 8 only the one base deletion is shown because it has slightly higher 
coverage). In humans, position 10 of the tRNA Glu-CTC has a known N2-methylguanosine 
modification, which may cause reverse transcriptase pausing during the cDNA step, potentially 
leading to the observed one base or three base deletion at exactly this position89. 
Lastly, it is evident from the coverage maps that the same parental tRNA can produce 
different primary tDRs depending on the tissue. For example, Gly-GCC-5-1 produces a tRH-
DTA in the colon samples, a tRH-5’ in the liver and seminal fluid samples, and a tRF-3’ in the 
neural progenitor samples (Figure 4.5A-D). 
Figure 6 shows two pre-tRNA coverage maps. Figure 4.6A is from an H1-derived 
mesendoderm sample, which has the highest expression of tDRs derived from pre-tRNAs (pre-
tDRs) among all samples analyzed, with 31% of its tRNA aligned reads mapping to pre-tRNAs. 
Figure 6B is from an inflamed section of colon tissue from a subject with Crohn’s disease, which 
has the highest expression of pre-tDRs among the primary tissue/fluid samples analyzed, with 
1.2% of its tRNA aligned reads mapping to pre-tRNAs. These coverage maps are similar to the 
coverage maps in Figure 5, but each dot is colored by location in the pre-tRNA instead of each 
individual base. We do not show each individual base because we are not indicating “error 
type”, since the algorithm searches only for exact matches to pre-tRNAs. The coverage maps in 
Figure 4.6 shows that reads can be derived from both the leader and trailer sequence, as well 
as from the region spanning the leader/trailer sequence and the tRNA body. 
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4.3c Analysis of different categories of cell types/tissues shows that tDR profiles are 
specific to tissue, disease and stage of differentiation 
 
Pearson correlation analysis of all pairs of samples across the four categories of 
datasets shows that tDR profiles correlate strongly between pairs of samples within the same 
cell type/tissue (median pair-wise r2 > 0.85, Figure 4.7A). This result is indicative of very little 
variability across individuals (or biological replicates in the case of the stem cells) in tDRs within 
the same tissue. Generally speaking tDR profiles were far less correlated between pairs of 
samples across categories; however, interestingly, 6/8 liver cancer samples correlated more 
strongly with the colon tissue samples (median pair-wise r2 = 0.91) than with the non-cancer 
liver samples (median pair-wise r2  = 0.42). The PCA plot shows several of the liver cancer 
samples closer to the colon samples than the non-cancer liver samples and the hierarchical 
clustering of the same data revealed that 6/8 liver cancer samples are in the same clade as the 
colon tissue samples (Figure 4.7B), supporting the Pearson correlation analysis (Figure 4.7A). 
The dominant tDR type produced from the same tRNA family sometimes varies across 
different samples (Figure 4.5 & 4.7C). For example, the dominant tDR derived from Val-AAC-2-
1, which produced a high abundance tDR in all samples, was a tRH-5’ in most colon, liver, and 
seminal fluid samples but a tRF-3’ in all of the stem and progenitor cells (Figure 4.7C & 4.7D). 
Another example is Glu-CTC-1-7, which produces a tRH-5’ in most of the primary tissue/fluid 
samples, the H1 cells, the trophoblasts, and the neural progenitor samples, but produces a tRH-
DA in the mesendoderm and mesenchymal stem cells. 
Reads corresponding to pre-tDRs represent 6-31% of all tDR reads in the 
stem/progenitor cells, >1% in two of the colon samples, and <1% in the rest of the samples. In 
the H1-derived cells, the most highly expressed pre-tDRs are pre-His-GTG-1-4-tRF-0 and pre-
Arg-CTC-2-1-tRH-1, which are tDRs derived from the header and leader sequences, 
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respectively. In the mesendoderm samples, which have the highest pre-tDR abundance among 
the samples analyzed, a pre-tDR (either pre-His-GTG-1-4-tRF-0 or pre-Arg-CTC-2-1-tRH-1, 
depending on the sample) is the third-most abundant tDR after Glu-CTC-1-7-tRH-DA and Glu-
CTC-2-1-tRH-DA. 
The primary tissue/fluid samples are characterized by a few very highly expressed tDRs 
(Figure 4.7D). Specifically, the colon samples and hepatitis B associated liver cancer samples 
are characterized primarily by tDRs derived from tRNA-Val genes, and the other liver samples 
by tDRs derived from tRNA-Gly genes. In contrast, the stem and progenitor cells, with the 
exception of the neural progenitor cells, are not dominated by a few highly expressed tDRs, but 
rather have many tDRs with moderate expression. 
 
4.4 Conclusions 
 
The biomedical significance of tDRs is becoming increasingly apparent and profiling 
tDRs from small RNA-seq data sets will define the cell type-specificity of tDRs and their 
chemical modifications. In this study we introduced a tool for mapping, naming, and quantifying 
tDRs, called tDRmapper, which is designed to handle the unique and challenging features of 
small RNAs derived from tRNAs. We analyzed small RNA-seq data from four different 
categories of cell types/tissues using tDRmapper and found that tDR profiles can differ 
dramatically across different tissues and disease states, that RNA modifications (as proxied by 
“error types”) vary by tissue and disease, and that different tDR species can be derived from the 
same parental tRNA depending on the tissue. tDRmapper not only provides a standardized 
nomenclature and quantification scheme for tDRs, but also includes graphical visualization that 
facilitates the discovery of novel tRNA and tDR biology. 
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4.5 Materials and Methods 
 
tDRmapper package 
tDRmapper is available on gitHub (https://github.com/sararselitsky/tDRmapper). The folder 
contains all the scripts needed for tDRmapper to run, the human tRNA FASTA file, detailed 
documentation, and the legend for the coverage maps. tDRmapper was written in Perl v.5.12.0 
and R v3.1.0. The coverage maps were generated using the ggplot2 R package. 
Defining the tRNA generalized secondary structure 
Structures of hg19 tRNAs were downloaded from gtRNAdb. The mode values of the D, anti-
codon, and T loops’ start and stop positions across all tRNAs were used to determine the 
“generalized” location of each loop. 
Figures and statistical analyses 
All statistical analyses were conducted using R. The hierarchical clustering was performed using 
the hclust R package and Ward’s method. The principal components analysis was computed 
using the R package prcomp. Figures 4-7 were produced with the R package gglot2.  
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Figure 4.1 Relative abundance of all tRNA-derived RNAs across four categories of human 
cell types/tissues. Proportion of trimmed and filtered reads that map to tRNAs in primary colon 
tissue (control n=13; Crohn’s disease uninflamed tissue, n= 21; Crohn’s disease inflamed 
tissue, n=6), primary liver tissue (control, n=4; chronic hepatitis B non-cancer tissue, n=4; 
chronic hepatitis C non-cancer tissue, n=4; chronic hepatitis B associated cancer tissue, n=4; 
chronic hepatitis C associated cancer tissue, n=4), the non-sperm fraction of seminal fluid (n=2), 
and NIH roadmap H1 and H1-derived cells (H1 cells with no treatment, n=2; H1-derived 
trophoblasts, n=2; H1-derived mesendoderm, n=2; H1-derived neuronal progenitor cells, n=2; 
H1-derived mesenchymal stem cells, n=2). Black lines show the median and interquartile range. 
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Figure 4.2 Schematic of tDRmapper. The input into tDRmapper is trimmed small RNA-seq 
reads. (Step 1) Reads are discarded if quality <28 at any position, length <14 or >41, or if the 
sequence does not occur >100 times in the FASTQ file. (Step 2) Reads are aligned according 
to a specific “error type hierarchy.” First reads are aligned, allowing for exact matches only to 
mature tRNA sequences, then reads that do not map are aligned allowing for exact matches to 
pre-tRNA sequences, and then reads that do not map are aligned allowing for one mismatch, 
then one deletion, two mismatches, two deletions, and then a three base pair deletion to mature 
tRNA sequences. (Step 3) tDRs are annotated based on size and location within either pre-
tRNA or mature tRNA. (Step 4) tDRs are quantified based on two features, the fraction of reads 
aligning to the parent tRNA and the maximum coverage across all positions of the tRNA. (Step 
5) tDRs are visualized as color-coded coverage maps. 
  
	  	   76 
 
 
Figure 4.3 Proportion of “error types” for specific tRNA-derived RNAs across different 
tissues and diseases. (A-D) Relative proportion of “error types” of reads mapping to (A) all 
tRNAs, (B) tRNA-Glu-CTC-1-7, (C) tRNA-Pro-CGG-1-3, (D) tRNA-Gly-GCC-1-5. 
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Figure 4.4 Diagrammatic representation of the naming scheme for tRNA-derived RNAs. 
(A & B) Left panel: color-coded structure of tRNAs to illustrate how tDRs are named. Colors in 
panel correspond to coverage maps in right panel. Right panel: Example tDRs identified in the 
datasets analyzed are shown. Size of dot represents percent of reads mapping at each position 
within each tRNA shown. (A) Naming scheme of tDRs derived from mature tRNAs. Numbers 
correspond to the “generalized” start and stop positions for each loop. Purple represents the D-
loop, “D”; green represents the anti-codon loop, “A”; dark green represents anti-codon triplet; 
and yellow represents T-loop, “T”. (B) Naming scheme of tDRs derived from pre-tRNAs. Red 
represents the leader sequence, “0”; orange represents the sequence of the tRNA body,”B”; and 
yellow represents the trailer sequence, “1”.  
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Figure 4.5 Examples of mature tRNA coverage maps from each category of human cell 
types/tissues. (A-D) Size of dot represents percent of reads mapping at each position within 
each tRNA. The color represents each individual nucleotide or the anti-codon positions. The 
dots overlaid in a variety of shapes represent each “error type” and the color of these shapes 
represents the proportion of each “error type” at each position. Coverage map for (A) primary 
colon tissue from control subject #31, (B) the non-sperm fraction of seminal fluid from subjects 
with prostate cancer, (C) primary non-cancerous liver tissue from subject #6 with chronic 
hepatitis B, and (D) H1-derived neural progenitor cells. 
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Figure 4.6 Example of pre-tRNA coverage maps. (A & B) Size of dot represents percent of 
reads mapping at each position within each tRNA. The color represents the location of the pre-
tRNA: leader sequence is red, the tRNA body is orange, and the trailer is yellow. Coverage map 
for (A) H1-derived mesendoderm cells and (B) primary tissue from the inflamed section of colon 
tissue from a subject with Crohn’s disease, #413. 
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Figure 4.7 Comparison of tDR profiles across four categories of human cell 
types/tissues. (A-D) tDR expression profiles for each human cell type/tissue; every tDR that 
has >5% relative abundance in any sample is included in the analysis. (A) Pearson correlation 
coefficient heat map. Each cell in the map represents the correlation coefficient between tDR 
expression profiles from different two samples. Cells along the diagonal represent identical 
samples and are colored in white. Thick white lines divide each category of data sets; thin white 
lines divide sub-categories of datasets within each category. Midpoint of color change for bar r2 
= 0. (B) Top panel: plot of principle components. Bottom panel: dendogram from hierarchical 
clustering of all tDR profiles. (C) Primary tDR species heat map. Each cell represents the 
dominant tDR species in each sample. (D) tDR expression heat map. Each cell represents the 
log10 of the relative tDR abundance of each tDR in each sample. 
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CONCLUSION 
 
HBV and HCV chronically infect hundreds of millions of people worldwide and together 
these viral infections are responsible for ~80% of HCC1. Numerous studies suggest that 
miRNAs are important in the pathogenesis of chronic viral hepatitis, but few unbiased 
approaches have been used9. Recently, tDRs have been studied in cell culture, found to be 
associated with disease, but have not been detected in human tissue and have not been 
studied in the context viral hepatitis or HCC. In this study, we assessed comprehensively the 
small RNA transcriptome in chronic viral hepatitis as well as in liver cancer associated with 
hepatitis virus infections using small RNA-seq of liver from Japanese subjects with advanced 
chronic hepatitis B or C and associated HCC. We defined the miRNA profile and determined 
miRNA master regulators, profiled the tDRs, and developed our own alignment method and 
annotation scheme, tDRmapper, which was made publically available. 
To determine the miRNA master regulators of each of these disease states, we 
performed an integrative analysis of gene and miRNA expression profiles from the microarray 
and small RNA-seq data, respectively. miR-21 and miR-27 were among the predicted master 
regulators of chronic viral hepatitis and cancer and they were both predicted to target genes 
involved in cholesterol synthesis. From our analyses in human hepatoma cells we found that the 
overexpression of either miR-21 or miR-27 significantly reduced cholesterol synthesis. miR-21’s 
effect was especially dramatic, reducing cholesterol synthesis by 70%. Follow-up studies should 
compare the effects of miR-21 on cholesterol synthesis compared to that of statins (common 
class of cholesterol reducing drugs which inhibits HMG-CoA reductase, encoded by HMGCR). If 
miR-21 is shown to be more effective, then it could be assessed for its potential as a 
therapeutic. However, due to carcinogenic6 and immune suppressing54 effects of miR-21, it may 
be too toxic to have potential as a therapeutic. 
We also assessed tDRs in chronic viral hepatitis and liver cancer. We observed that 
tDRs were abundant and significantly increased in chronic viral hepatitis. Remarkably, total 
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abundance of tDRs exceeded that of miRNAs in most infected non-cancerous tissues. In 
cancer, total tDR abundance was reduced and relative abundance of individual tDRs was 
dramatically altered. Exploration into how and why tDR abundance was reduced and altered in 
cancer compared to the non-cancer tissue may lead to a greater understanding of tDR biology 
and hypotheses of the function of tDRs. 
 Two specific tDRs assessed by RTq-PCR were highly increased in the chronic hepatitis 
B and C human samples compared to the uninfected control samples, but for chimpanzees, the 
increase was observed only in the chronic hepatitis B samples. Chronic infections with HBV and 
HCV typically lead to more severe liver disease in human patients than in the chimpanzee 
model37,38. Disease severity may account for the differences we observed in hepatic tDR 
abundance between humans and chimpanzees with chronic HCV infection. However, because 
humans and chimpanzees exhibited a similar significant increase in tDR abundance in chronic 
hepatitis B, we suggest that there may be a primary HBV-specific mechanism that directly 
regulates tDR biogenesis and stability. The role of HBV in regulating tDRs should be 
investigated further. 
To enable the tDR research community to better annotate, quantify, and visualize tDRs, 
we developed a publically available tool, tDRmapper. We applied the method to four difference 
categories of datasets and demonstrated that RNA modifications vary by tRNA family, tissue, 
and disease state. tDRmapper was designed specifically for human small RNA-seq data (single-
end, 50x) generated on the Illumina sequencing platform using cDNA libraries that were 
prepared with the Illumina TruSeq protocol. tDRmapper could be improved upon in the future to 
be able to read different types of small RNA-seq data, such as those with Phred+64 scores. 
tDRmapper could also be modified to accomodate other species besides human, given that 
tDRs are commonly assessed in organisms such as mice90 and trypanosomes21. Improved 
experimental and computational methods of tDR detection and quantification will facilitate 
discovery of novel roles for tDRs in human disease. 
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